

-
- ^{*}Correspondence: Mónica V. Cunha, Centre for Ecology, Evolution and Environmental
24 Changes (cE3c), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016
25 Lisboa, Portugal. Email: <u>mscunha@ciencias.uli</u> 24 Changes (cE3c), Faculdade de Ciências, Universidade de Lisboa, Campo Grande, 1749-016
- 25 Lisboa, Portugal. Email: mscunha@ciencias.ulisboa.pt

26 **ABSTRACT**
27 As the CO\
28 surveillance s
29 the pandemi 27 As the COVID-19 pandemic reached its peak, many countries implemented genomic
28 surveillance systems to track the evolution and transmission of SARS-CoV-2. Transition from
29 the pandemic to the endemic phase prioritiz 28 surveillance systems to track the evolution and transmission of SARS-CoV-2. Transition from
29 the pandemic to the endemic phase prioritized alternative testing strategies to maintain
20 effective epidemic surveillance the pandemic to the endemic phase prioritized alternative testing strategies to maintain

20 effective epidemic surveillance at the population level, with less intensive sequencing efforts.

21 One such promising approach effective epidemic surveillance at the population level, with less intensive sequencing efforts.
31 One such promising approach was Wastewater-Based Surveillance (WBS), which offers
32 non-invasive, cost-effective means fo 31 One such promising approach was Wastewater-Based Surveillance (WBS), which offers
32 non-invasive, cost-effective means for analysing virus trends at the sewershed level. From
33 2020 onwards, wastewater has been recogn non-invasive, cost-effective means for analysing virus trends at the sewershed level. From
33 2020 onwards, wastewater has been recognized as an instrumental source of information for
34 public health, with national and in 2020 onwards, wastewater has been recognized as an instrumental source of information for

public health, with national and international authorities exploring options to implement

national wastewater surveillance systems public health, with national and international authorities exploring options to implement
national wastewater surveillance systems and increasingly relying on WBS as early warning
of potential pathogen outbreaks. In Portug national wastewater surveillance systems and increasingly relying on WBS as early warning
36 of potential pathogen outbreaks. In Portugal, several pioneer projects joined the academia,
37 water utilities and Public Adminis 36 of potential pathogen outbreaks. In Portugal, several pioneer projects joined the academia,
37 water utilities and Public Administration around WBS.
38 To validate WBS as an effective genomic surveillance strategy, it i

water utilities and Public Administration around WBS.
38 To validate WBS as an effective genomic surveillan
39 term performance data. In this work, we present 38 To validate WBS as an effective genomic surveillance strategy, it is crucial to collect long
39 term performance data. In this work, we present one year of systematic SARS-CoV-2
30 wastewater surveillance in Portugal, r wastewater surveillance in Portugal, representing 35% of the mainland population. We
41 employed two complementary methods for lineage determination - allelic discrimination by
42 RT-PCR and S gene sequencing. This combina wastewater surveillance in Portugal, representing 35% of the mainland population. We

41 employed two complementary methods for lineage determination - allelic discrimination by

42 RT-PCR and S gene sequencing. This combi employed two complementary methods for lineage determination - allelic discrimination by

42 RT-PCR and S gene sequencing. This combination allowed us to monitor variant evolution in

143 near-real-time and identify low-fr RT-PCR and S gene sequencing. This combination allowed us to monitor variant evolution in

143 near-real-time and identify low-frequency mutations.

144 Over the course of this year-long study, spanning from May 2022 to Ap

near-real-time and identify low-frequency mutations.
44 Over the course of this year-long study, spannir
45 successfully tracked the dominant Omicron sub-lin Over the course of this year-long study, spanning from May 2022 to April 2023, we
successfully tracked the dominant Omicron sub-lineages, their progression and evolution,
which aligned with concurrent clinical surveillance successfully tracked the dominant Omicron sub-lineages, their progression and evolution,
which aligned with concurrent clinical surveillance data. Our results underscore the
effectiveness of WBS as a tracking system for vi which aligned with concurrent clinical surveillance data. Our results underscore the
effectiveness of WBS as a tracking system for virus variants, with the ability to unveil
mutations undetected via massive sequencing of c 48 mutations undetected via massive sequencing of clinical samples from Portugal,
49 demonstrating the ability of WBS to uncover new mutations and detect rare genetic variants.
50 Our findings emphasize that knowledge of t mutations undetected via massive sequencing of clinical samples from Portugal,
demonstrating the ability of WBS to uncover new mutations and detect rare genetic variants.
50 Our findings emphasize that knowledge of the gen

demonstrating the ability of WBS to uncover new mutations and detect rare genetic variants.
50 Our findings emphasize that knowledge of the genetic diversity of SARS-CoV-2 at the
51 population level can be extended far bey 50 Our findings emphasize that knowledge of the genetic diversity of SARS-CoV-2 at the
51 population level can be extended far beyond via the combination of routine clinical genomic
52 surveillance with wastewater sequenci 51 population level can be extended far beyond via the combination of routine clinical genomic
52 surveillance with wastewater sequencing and genotyping.
3 52 surveillance with wastewater sequencing and genotyping.

53

54
55 54 **KEYWORDS**
55 SARS-CoV-2;
56 sequencing; Q 55 SARS-CoV-2; Spike gene sequencing; Wastewater-Based Surveillance; Wastewater
56 sequencing; Genomic variants.
57 56 sequencing; Genomic variants.
57
58 INTRODUCTION

--
58
59 58 **INTRODUCTION**
59 During the coron
60 respiratory syndro
61 wastewater surve 59 During the coronavirus disease 2019 (COVID-19) pandemic, detection of severe acute
60 respiratory syndrome coronavirus 2 (SARS-CoV-2) in faeces accelerated the introduction of
61 wastewater surveillance in a variety of 60 respiratory syndrome coronavirus 2 (SARS-CoV-2) in faeces accelerated the introduction of
61 wastewater surveillance in a variety of settings, including cities, airports, hospitals, and
62 university campuses (Agrawal e wastewater surveillance in a variety of settings, including cities, airports, hospitals, and

university campuses (Agrawal et al., 2021; Medema et al., 2020; Nkambule et al., 2023). At

the population level, wastewater-bas university campuses (Agrawal et al., 2021; Medema et al., 2020; Nkambule et al., 2023). At
the population level, wastewater-based surveillance (WBS) has been implemented solely as
a complementary method to clinical surveil 64 a complementary method to clinical surveillance (Peccia et al., 2020). However, WBS
65 enabled correlating the real-time information of SARS-CoV-2 viral loads in sewage with the
66 increase of positive cases and hospita 64 a complementary method to clinical surveillance (Peccia et al., 2020). However, WBS
65 enabled correlating the real-time information of SARS-CoV-2 viral loads in sewage with the
66 increase of positive cases and hospita enabled correlating the real-time information of SARS-CoV-2 viral loads in sewage with the
increase of positive cases and hospitalizations (Galani et al., 2022; Perez-Zabaleta et al.,
2023), in addition to the identificati 67 2023), in addition to the identification of outbreak hotspots within a given region at the
68 sewershed level (Fontenele et al., 2021; Medema et al., 2020; Monteiro et al., 2022).
69 Moreover, WBS has also enabled detec 2023), in addition to the identification of outbreak hotspots within a given region at the
68 sewershed level (Fontenele et al., 2021; Medema et al., 2020; Monteiro et al., 2022).
69 Moreover, WBS has also enabled detectio 68 sewershed level (Fontenele et al., 2021; Medema et al., 2020; Monteiro et al., 2022).
Moreover, WBS has also enabled detection of novel SARS-CoV-2 mutations in urban
wastewater, which had not been detected by standard c 69 Moreover, which had not been detected by standard clinical surveillance (Karthikeyan et al., 2022; Smyth et al., 2022). WBS has thus become a public health instrument helping to track SARS-CoV-2 spread. 10 al., 2022; Smyth et al., 2022). WBS has thus become a public health instrument helping to
12 track SARS-CoV-2 spread.
13 Given the potential contribution of both symptomatic and asymptomatic shedder individuals 12 al., 2022; Smyth et al., 2022). WBS has thus become a public health instrument helping to
12 track SARS-CoV-2 spread.
13 Given the potential contribution of both symptomatic and asymptomatic shedder individuals
14 to SA

track SARS-CoV-2 spread.
73 Given the potential contribu
74 to SARS-CoV-2 viral load in
75 al 2020) wastewater surv Given the potential contribution of both symptomatic and asymptomatic shedder individuals

to SARS-CoV-2 viral load in sewage (Elsamadony et al., 2021; Foladori et al., 2020; Wu et

al., 2020), wastewater surveillance pres to SARS-CoV-2 viral load in sewage (Elsamadony et al., 2021; Foladori et al., 2020; Wu et
al., 2020), wastewater surveillance presents a less biased and resource-effective approach
for obtaining an overview of the viral di 2020), wastewater surveillance presents a less biased and resource-effective approach

176 for obtaining an overview of the viral diversity circulating in a community, in contrast to the

177 currently dominant approach of currently dominant approach of clinical genomic surveillance. Therefore, in recognition of the 27 currently dominant approach of clinical genomic surveillance. Therefore, in recognition of the

178 immense potential of WBS, the European Commission recommended to Member States the

178 78 immense potential of WBS, the European Commission recommended to Member States the

It is made available under a CC-BY-ND 4.0 International license. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297774;](https://doi.org/10.1101/2023.10.30.23297774) this version posted October 31, 2023. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted

mplementation of regular SARS-CoV-2 monitoring through molecular analyses and
30 sequencing of wastewater (*Commission Recommendation (EU) 2021/472*, 2021). Hence, a
31 considerable number of studies with diverse aims, fro sequencing of wastewater (*Commission Recommendation (EU) 2021/472*, 2021). Hence, a
81 considerable number of studies with diverse aims, from establishing methodologies to finding
82 new mutations, have reported results f considerable number of studies with diverse aims, from establishing methodologies to finding
82 new mutations, have reported results from WBS of European sub-populations (Agrawal et
81 al., 2021; Amman et al., 2022; Galani new mutations, have reported results from WBS of European sub-populations (Agrawal et al., 2021; Amman et al., 2022; Galani et al., 2022; Izquierdo-Lara et al., 2021, 2023; Katharina et al., 2022; La Rosa et al., 2023; Med al., 2021; Amman et al., 2022; Galani et al., 2022; Izquierdo-Lara et al., 2021, 2023;
Katharina et al., 2022; La Rosa et al., 2023; Medema et al., 2020; Monteiro et al., 2022;
Pérez-Cataluña et al., 2022; Perez-Zabaleta e 84 Katharina et al., 2022; La Rosa et al., 2023; Medema et al., 2020; Monteiro et al., 2022;
85 Pérez-Cataluña et al., 2022; Perez-Zabaleta et al., 2023). However, it is important to note
86 that such studies are not limit Pérez-Cataluña et al., 2022; Perez-Zabaleta et al., 2023). However, it is important to note
that such studies are not limited to Europe; similar investigations have been conducted in
American (Crits-Christoph et al., 2021; that such studies are not limited to Europe; similar investigations have been conducted in
87 American (Crits-Christoph et al., 2021; Fontenele et al., 2021; Gregory et al., 2022;
88 Karthikeyan et al., 2022; Nemudryi et a 88 Karthikeyan et al., 2022; Nemudryi et al., 2020; Peccia et al., 2020; Sapoval et al., 2023;
89 Silva et al., 2022; Smyth et al., 2022; Swift et al., 2022) and Asian (Bar-Or et al., 2021) sub-
90 populations as well. The Karthikeyan et al., 2022; Nemudryi et al., 2020; Peccia et al., 2020; Sapoval et al., 2023;
Silva et al., 2022; Smyth et al., 2022; Swift et al., 2022) and Asian (Bar-Or et al., 2021) sub-
populations as well. The data col 89 Silva et al., 2022; Smyth et al., 2022; Swift et al., 2022) and Asian (Bar-Or et al., 2021) sub-
80 populations as well. The data collected are of significant importance for comprehending
81 methodological challenges an 90 populations as well. The data collected are of significant importance for comprehending
91 methodological challenges and uncertainty sources, comparing the performance of WBS
92 versus clinical surveillance, and extract methodological challenges and uncertainty sources, comparing the performance of WBS
92 versus clinical surveillance, and extracting additional valuable information from WBS data.
93 The COVID-19 pandemic has been character

versus clinical surveillance, and extracting additional valuable information from WBS data.

93 The COVID-19 pandemic has been characterized by the sequential emergence of various

94 variants of interest and variants of c The COVID-19 pandemic has been characterized by the sequential emergence of various

94 variants of interest and variants of concern (VOC), with the most recent being Omicron

95 (pangolin lineage B.1.1.529), initially ide variants of interest and variants of concern (VOC), with the most recent being Omicron
95 (pangolin lineage B.1.1.529), initially identified in November 2021 (Rambaut et al., 2020;
96 WHO, 2023). These VOCs are characteriz 95 (pangolin lineage B.1.1.529), initially identified in November 2021 (Rambaut et al., 2020;
96 WHO, 2023). These VOCs are characterized by constellations of mutations that, to various
97 degrees, appear to impact on viru WHO, 2023). These VOCs are characterized by constellations of mutations that, to various
97 degrees, appear to impact on virus transmissibility, clinical outcome, evasion from vaccine-
98 derived adaptive immune responses, degrees, appear to impact on virus transmissibility, clinical outcome, evasion from vaccine-
98 derived adaptive immune responses, and effectiveness of diagnostic tests (Khateeb et al.,
2021; Kuzmina et al., 2022; Tao et a derived adaptive immune responses, and effectiveness of diagnostic tests (Khateeb et al.,

99 2021; Kuzmina et al., 2022; Tao et al., 2021). To date, wastewater analysis has routinely

90 employed two approaches: (i) rever 2021; Kuzmina et al., 2022; Tao et al., 2021). To date, wastewater analysis has routinely

100 employed two approaches: (i) reverse transcription quantitative PCR (RT-qPCR) or reverse

101 transcription-droplet digital PCR 102 eand (ii) high-throughput sequencing for monitorization of SARS-CoV-2 mutations and
103 variants (Bar-Or et al., 2021; Crits-Christoph et al., 2021; Nemudryi et al., 2020). Although transcription-droplet digital PCR (RT-ddPCR) for SARS-CoV-2 detection and quantification;
102 and (ii) high-throughput sequencing for monitorization of SARS-CoV-2 mutations and
103 variants (Bar-Or et al., 2021; Crits-Chri and (ii) high-throughput sequencing for monitorization of SARS-CoV-2 mutations and
103 variants (Bar-Or et al., 2021; Crits-Christoph et al., 2021; Nemudryi et al., 2020). Although
104 PCR-based wastewater surveillance ena variants (Bar-Or et al., 2021; Crits-Christoph et al., 2021; Nemudryi et al., 2020). Although
104 PCR-based wastewater surveillance enables the quick and highly sensitive detection and
105 quantification of virus load in s 104 PCR-based wastewater surveillance enables the quick and highly sensitive detection and
105 quantification of virus load in sewage, with the possibility to target specific viral mutations, it
106 can provide limited inf quantification of virus load in sewage, with the possibility to target specific viral mutations, it
106 can provide limited information on which lineages and/or variants are circulating, because the
5 106 can provide limited information on which lineages and/or variants are circulating, because the
5
5

number of diagnosing mutations has greatly decreased with the increase of viral genetic
108 diversity concurrent with the expansion of the Omicron VOC. Tracking SARS-CoV-2 genetic
109 diversity thus became essential to det diversity concurrent with the expansion of the Omicron VOC. Tracking SARS-CoV-2 genetic
109 diversity thus became essential to detect precociously the emergence of novel SARS-CoV-2
110 variants with potentially higher tran diversity thus became essential to detect precociously the emergence of novel SARS-CoV-2
110 variants with potentially higher transmissibility and/or immune evasion properties, demanding
111 rapid, cost-efficient, and acce variants with potentially higher transmissibility and/or immune evasion properties, demanding
111 rapid, cost-efficient, and accessible methods.
112 In this work, we aimed to monitor SARS-CoV-2 variant evolution in near-re

111 rapid, cost-efficient, and accessible methods.
112 In this work, we aimed to monitor SARS-C
113 identify both major and low-frequency mutati 112 In this work, we aimed to monitor SARS-CoV-2 variant evolution in near-real-time and
113 identify both major and low-frequency mutations. For that purpose, we present one year of
114 systematic SARS-CoV-2 wastewater su identify both major and low-frequency mutations. For that purpose, we present one year of
114 systematic SARS-CoV-2 wastewater surveillance in Portugal, during the implementation of
115 the European Commission (EC) Recomme systematic SARS-CoV-2 wastewater surveillance in Portugal, during the implementation of
the European Commission (EC) Recommendation no. 2021/472, representing about 35% of
the mainland population. We performed a combined a the European Commission (EC) Recommendation no. 2021/472, representing about 35% of
116 the mainland population. We performed a combined approach, using a series of allele-
117 specific RT-PCR assays targeting a panel of s the mainland population. We performed a combined approach, using a series of allele-
117 specific RT-PCR assays targeting a panel of six Omicron associated mutations chosen to
118 differentiate the most prevalent circulati 117 specific RT-PCR assays targeting a panel of six Omicron associated mutations chosen to
118 differentiate the most prevalent circulating lineages, and targeted Illumina sequencing of the
119 Spike (S) gene of wastewater 118 differentiate the most prevalent circulating lineages, and targeted Illumina sequencing of the

119 Spike (S) gene of wastewater samples recovered in Portugal between May 2022 and April

120 2023. 119 Spike (S) gene of wastewater samples recovered in Portugal between May 2022 and April
120 2023.
121 120 2023.
121
|

**MATERIALS AND METHODS
123 Study design, wastewater sai
124 The national surveillance s
125 Recommendation no 2021/4 Study design, wastewater sampling and SARS-CoV-2 detection**
124 The national surveillance system set up during the imple
125 Recommendation no. 2021/472 in Portugal aimed to cover a
126 Portuguese population Given the dim The national surveillance system set up during the implementation of the EC
125 Recommendation no. 2021/472 in Portugal aimed to cover a significant part of the
126 Portuguese population. Given the dimension of the agglome 125 Recommendation no. 2021/472 in Portugal aimed to cover a significant part of the
126 Portuguese population. Given the dimension of the agglomerations on the national territory,
127 the wastewater treatment plants (WWTP Portuguese population. Given the dimension of the agglomerations on the national territory,
127 the wastewater treatment plants (WWTPs) monitored for SARS-CoV-2 were selected based
128 on facilities serving more than 10000 127 the wastewater treatment plants (WWTPs) monitored for SARS-CoV-2 were selected based
128 on facilities serving more than 100000 equivalent population and by excluding WWTPs with a
129 strong industrial component. Monit on facilities serving more than 100000 equivalent population and by excluding WWTPs with a
129 strong industrial component. Monitorization focused on 14 WWTPs from the largest cities of
130 the country, reflecting 34.2% of the country, reflecting 34.2% of the mainland population. One litre of 24-hour composite raw
131 wastewater samples was collected twice a week from 14 WWTPs located in the North
132 (number of WWTPs n=4) Center (n=2) Lisbo wastewater samples was collected twice a week from 14 WWTPs located in the North
132 (number of WWTPs, n=4), Center (n=2), Lisbon and Tagus Valley (LTV) (n=4), and Algarve
133 (n=4) regions (Figure S1), with a population 132 (number of WWTPs, n=4), Center (n=2), Lisbon and Tagus Valley (LTV) (n=4), and Algarve
133 (n=4) regions (Figure S1), with a population equivalent ranging from 113200 to 920000.
134 Wastewater collection took place be 132 (*number of WWTPs*, n=4), Center (*n*=2), Lisbon and Tagus Valley (LTV) (*n*=4), and Algarve

133 (*n*=4) regions (Figure S1), with a population equivalent ranging from 113200 to 920000.

134 Wastewater collection took (*n*=4) regions (Figure S1), with a population equivalent ranging from 113200 to 920000.
134 Wastewater collection took place between May 2022 and April 2023 resulting in a total of
135 1339 samples.
Wastewater processing

135 1339 samples.
136 Wastewater processing, RNA extraction, detection, and quantification were performed as
137 previously described by Monteiro *et al.* 2022 (Monteiro et al., 2022). The SARS-CoV-2 viral 135 1339 samples.
136 Wastewater previously desc
138 Load in each s 137 previously described by Monteiro *et al.* 2022 (Monteiro et al., 2022). The SARS-CoV-2 viral
138 Ioad in each sample was estimated via viral RNA detection through RT-qPCR using the
139 Charité assays: the E Sarbecco as previously described by Monteiro *et al.* 2022 (Monteiro et al., 2022). The SARS-CoV-2 viral
138 load in each sample was estimated via viral RNA detection through RT-qPCR using the
139 Charité assays: the E_Sarbecco assay load in each sample was estimated via viral RNA detection through RT-qPCR using the

Charité assays: the E_Sarbecco assay targeting the envelope protein gene, the RdRp assay

140 the nucleon the RNA-dependent RNA polymeras 139 Charité assays: the E_Sarbecco assay targeting the envelope protein gene, the RdRp assay

140 targeting the RNA-dependent RNA polymerase gene, and the N_Sarbecco assay targeting

141 the nucleoprotein (Corman et al., targeting the RNA-dependent RNA polymerase gene, and the N_Sarbecco assay targeting
141 the nucleoprotein (Corman et al., 2020). For these, the one-step RT-qPCR assays AgPath-
142 ID™ One-Step RT-PCR (Thermo Fisher Scient 141 the nucleoprotein (Corman et al., 2020). For these, the one-step RT-qPCR assays AgPath-

142 ID™ One-Step RT-PCR (Thermo Fisher Scientific, USA) were used as described before

143 (Monteiro et al., 2022).

144 142 ID™ One-Step RT-PCR (Thermo Fisher Scientific, USA) were used as described before
143 (Monteiro et al., 2022).
144 **Allelic discrimination analysis to detect Omicron associated mutations in wastewater**

143 (Monteiro et al., 2022).
144
145 **Allelic discrimination**
146 **samples** 144
145
146
147

Allelic discrimination analysis to detect Omicron associated mutations in wastewater
146 samples
147 A set of six commercially available probe-based genotyping RT-PCR assays was used for
148 the identification of mutations 146 **samples**
147 A set of s
148 the identi
149 allele disc 148 the identification of mutations associated to specific Omicron sub-lineages. The panel of
149 allele discrimination assays was continuously updated throughout the sampling period to 148 the identification of mutations associated to specific Omicron sub-lineages. The panel of
149 allele discrimination assays was continuously updated throughout the sampling period to
149 allele discrimination assays was 149 allele discrimination assays was continuously updated throughout the sampling period to

7

7

accommodate variation within circulating Omicron sub-lineages, as assessed by clinical
151 epidemiologic surveillance (Figure S2). These genotyping assays targeted specific amino
152 acid changes, namely G339D, L452R, Q493 epidemiologic surveillance (Figure S2). These genotyping assays targeted specific amino
152 acid changes, namely G339D, L452R, Q493R and T475K at S gene, D3N at M gene, and
153 L11F at ORF7b (Table S1).
154 Genotyping assa acid changes, namely G339D, L452R, Q493R and T475K at S gene, D3N at M gene, and
153 L11F at ORF7b (Table S1).
154 Genotyping assays were performed using the TaqMan SARS-CoV-2 Mutation Panel
155 (Thermo Eisher Scientific U

L11F at ORF7b (Table S1).
153 L11F at ORF7b (Table S1).
154 Genotyping assays were performed using the TaqMan SARS-CoV-2 Mutation Panel
155 (Thermo Fisher Scientific, USA) following the manufacturer's instructions. Each r 155 (Thermo Fisher Scientific, USA) following the manufacturer's instructions. Each reaction
156 consisted of 5 µL of wastewater RNA, mixed with 4X TaqPath™ 1-Step RT-qPCR Master
157 Mix CG (Thermo Fisher Scientific, USA) consisted of 5 µL of wastewater RNA, mixed with 4X TaqPath™ 1-Step RT-qPCR Master
157 Mix CG (Thermo Fisher Scientific, USA) and 40X TaqMan probes (Thermo Fisher Scientific,
158 USA), in a final volume of 20 µL. Each assa 156 consisted of 5 μL of wastewater RNA, mixed with 4X TaqPath™ 1-Step RT-qPCR Master
157 Mix CG (Thermo Fisher Scientific, USA) and 40X TaqMan probes (Thermo Fisher Scientific,
158 USA), in a final volume of 20 μL. Each Mix CG (Thermo Fisher Scientific, USA) and 40X TaqMan probes (Thermo Fisher Scientific,
158 USA), in a final volume of 20 µL. Each assay included sequence-specific forward and
159 reverse primers to amplify the target regi USA), in a final volume of 20 μL. Each assay included sequence-specific forward and
159 reverse primers to amplify the target region and two TaqMan minor groove binder (MGB)
160 probes with non-fluorescent quenchers (NFQ) 159 reverse primers to amplify the target region and two TaqMan minor groove binder (MGB)
160 probes with non-fluorescent quenchers (NFQ) to detect the PCR-amplification fragments:
161 one FAM dye-labelled probe binds the 160 probes with non-fluorescent quenchers (NFQ) to detect the PCR-amplification fragments:
161 one FAM dye-labelled probe binds the mutated gene, and one VIC dye-labelled probe binds
162 the wild-type SARS-CoV-2 gene.
163 one FAM dye-labelled probe binds the mutated gene, and one VIC dye-labelled probe binds
162 the wild-type SARS-CoV-2 gene.
163 PCR cycling was performed on a StepOne™ Real-Time PCR System (Applied
164 Biosystems™) under t

162 the wild-type SARS-CoV-2 gene.
163 PCR cycling was performed
164 Biosystems™), under the followir
165 Tag polymerase activation at 95 PCR cycling was performed on a StepOne™ 163 PCR cycling was performed on a StepOne^{1M} Real-Time PCR System (Applied
164 BiosystemsTM), under the following conditions: reverse transcription at 45°C for 15 minutes,
165 Taq polymerase activation at 95°C for 2 m BiosystemsTM), under the following conditions: reverse transcription at 45^oC for 15 minutes, Biosystems^{1M}), under the following conditions: reverse transcription at 45°C for 15 minutes,
165 Taq polymerase activation at 95°C for 2 minutes, followed by 45 cycles of denaturation at
166 95°C for 15 seconds, and ann Taq polymerase activation at 95°C for 2 minutes, followed by 45 cycles of denaturation at
166 95°C for 15 seconds, and annealing at 58°C for 45 seconds, with a final post-read for 30
167 seconds at 60°C. All RT-PCR experim 95°C for 15 seconds, and annealing at 58°C for 45 seconds, with a final post-read for 30
167 seconds at 60°C. All RT-PCR experiments included a no-template control (NTC) (*i.e.*,
168 DNase/RNase free water), and a wild-typ 167 seconds at 60°C. All RT-PCR experiments included a no-template control (NTC) (*i.e.*,
168 DNase/RNase free water), and a wild-type AcroMetrix Coronavirus 2019 (COVID-19) RNA
169 control (RUO) (Thermo Fisher Scientific)

170 Allelic discrimination results were then visualized on a scatter plot, contrasting reporter dye
171 fluorescence (*i.e.*, mutated allele versus wild type allele), and analyzed using QuantStudio control (RUO) (Thermo Fisher Scientific).
170 Allelic discrimination results were then vi
171 fluorescence (*i.e.*, mutated allele versus
172 Design and Analysis Software version 2.5 Allelic discrimination results were then visualized on a scatter plot, contrasting reporter dye
171 fluorescence (*i.e.*, mutated allele versus wild type allele), and analyzed using QuantStudio
172 Design and Analysis Soft 171 fluorescence (*i.e.*, mutated allele versus wild type allele), and analyzed using QuantStudio
172 Design and Analysis Software version 2.5, via the genotyping analysis module with real-time
173 data. Design and Analysis Software version 2.5, via the genotyping analysis module with real-time
data.
174 S gene sequencing and reference-based analyses

173 data.
174
175 **S ger**
176 From

176
177 From the complete set of samples, 332 were selected for S gene sequencing. These 176 From the complete set of samples, 332 were selected for S gene sequencing. These
177 corresponded to two samples per month and per WWTP, as defined in the EC
8 177 corresponded to two samples per month and per WWTP, as defined in the EC
8

Recommendation. Whenever possible, the samples selected for sequencing were those that

179 exhibited RT-qPCR amplification of at least two SARS-CoV-2 genes (E, N, or RdRp), with

180 threshold cycle (Ct) values below 36, exhibited RT-qPCR amplification of at least two SARS-CoV-2 genes (E, N, or RdRp), with
threshold cycle (Ct) values below 36, which were found to yield more genome coverage.
Samples with higher Ct values were preferentially threshold cycle (Ct) values below 36, which were found to yield more genome coverage.
181 Samples with higher Ct values were preferentially avoided to ensure best quality sequencing
182 results and facilitate accurate SARS Samples with higher Ct values were preferentially avoided to ensure best quality sequencing
182 results and facilitate accurate SARS-CoV-2 variant/lineage assignment.
183 The RNA from the wastewater samples was purified wi

results and facilitate accurate SARS-CoV-2 variant/lineage assignment.
183 The RNA from the wastewater samples was purified with RNeasy I
184 (Qiagen), following the manufacturer's instructions, to eliminate impuriti
185 C The RNA from the wastewater samples was purified with RNeasy MinElute Cleanup kit

(Qiagen), following the manufacturer's instructions, to eliminate impurities and inhibitors that

could potentially interfere with the subs (Qiagen), following the manufacturer's instructions, to eliminate impurities and inhibitors that
185 could potentially interfere with the subsequent sequencing process. Total RNA was then
186 quantified using the Qubit RNA could potentially interfere with the subsequent sequencing process. Total RNA was then

186 quantified using the Qubit RNA HS Assay kit (Thermo Fisher Scientific, USA), following the

187 manufacturer's instructions. Sampl manufacturer's instructions. Samples with RNA concentrations above 20 ng/µl were selected
188 for SARS-CoV-2 sequencing.
189 The SARS-CoV-2 target amplicon libraries were constructed using ARTIC SARS-CoV-2 RNA manufacturer's instructions. Samples with RNA concentrations above 20 ng/μl were selected
188 for SARS-CoV-2 sequencing.
189 The SARS-CoV-2 target amplicon libraries were constructed using ARTIC SARS-CoV-2 RNA
190 Fibrary

188 for SARS-CoV-2 sequencing.
189 The SARS-CoV-2 target ampl
190 library (Eurofins, Konstanz, Gr
191 Sequencing occurred using 1 190 library (Eurofins, Konstanz, Germany), which was especially designed to amplify the S gene.
191 Sequencing occurred using the Illumina NovaSeq 6000, according to the manufacturer's
192 specifications, with the paired-e 190 library (Eurofins, Konstanz, Germany), which was especially designed to amplify the S gene.
191 Sequencing occurred using the Illumina NovaSeq 6000, according to the manufacturer's
192 specifications, with the paired-e 191 Sequencing occurred using the Illumina NovaSeq 6000, according to the manufacturer's
192 specifications, with the paired-end module (2x150 bp) attachment. Eurofins sequencing
193 strategy was optimized for the S gene s 193 strategy was optimized for the S gene sequencing in wastewater samples, with the
194 application of 49 primers, including 22 primer pairs with 5 alternative primers to account for
195 variability in the primer binding 193 strategy was optimized for the S gene sequencing in wastewater samples, with the
194 application of 49 primers, including 22 primer pairs with 5 alternative primers to account for
195 variability in the primer binding 194 application of 49 primers, including 22 primer pairs with 5 alternative primers to account for
195 variability in the primer binding region. The 22 amplicons ranged in size from 200 to 250
196 base pairs, and collectiv variability in the primer binding region. The 22 amplicons ranged in size from 200 to 250
196 base pairs, and collectively cover the entire S-gene sequence, spanning 3822 base pairs.
197 Read processing, reference-based al

base pairs, and collectively cover the entire S-gene sequence, spanning 3822 base pairs.
197 Read processing, reference-based alignment and variant analysis were performed us
198 bioinformatics tools available in the Galax Read processing, reference-based alignment and variant analysis were performed using
198 bioinformatics tools available in the Galaxy EU server (Afgan et al., 2018). Quality control
199 reports were generated with FastQC (198 bioinformatics tools available in the Galaxy EU server (Afgan et al., 2018). Quality control
199 reports were generated with FastQC (Galaxy version 0.11.9) using default parameters. Raw
100 reads were cleaned up from a 1990 reads were cleaned up from adaptors (-ILLUMINACLIP) and low quality nucleotides (-
1991 SLIDINGWINDOW:4:30) using Trimmomatic (Galaxy version 0.38) (Bolger et al., 2014).
1992 Quality trimmed reads were aligned to the 201 SLIDINGWINDOW:4:30) using Trimmomatic (Galaxy version 0.38) (Bolger et al., 2014).
202 Quality trimmed reads were aligned to the SARS-CoV-2 reference genome (NCBI accession
203 number NC_045512.2) using the Burrows-Whe Quality trimmed reads were aligned to the SARS-CoV-2 reference genome (NCBI accession
203 number NC_045512.2) using the Burrows-Wheeler Aligner (Galaxy version 0.7.17) (Li, 2013)
204 with default parameters: and reads with Quality trimmed reads were aligned to the SARS-CoV-2 reference genome (NCBI accession
203 number NC_045512.2) using the Burrows-Wheeler Aligner (Galaxy version 0.7.17) (Li, 2013)
204 with default parameters; and reads with 203 number NC_045512.2) using the Burrows-Wheeler Aligner (Galaxy version 0.7.17) (Li, 2013)
204 with default parameters; and reads with less than 35 bp were removed, using BAM filter
205 (Galaxy version 0.5.9) in order to with default parameters; and reads with less than 35 bp were removed, using BAM filter
205 (Galaxy version 0.5.9) in order to eliminate primers and short uninformative reads. Variant
9 205 (Galaxy version 0.5.9) in order to eliminate primers and short uninformative reads. Variant

calling was performed using iVar pipeline (Galaxy version 1.4.2) (Grubaugh et al., 2019), with
207 the minimum quality score threshold to count a base being set to 20, and the minimum
208 frequency threshold to 0.03. The m 207 the minimum quality score threshold to count a base being set to 20, and the minimum
208 frequency threshold to 0.03. The minimum number of reads to consider major variants
209 (polymorphism with a frequency between 0. 208 frequency threshold to 0.03. The minimum number of reads to consider major variants
209 (polymorphism with a frequency above 0.5) was set to 10, while for minor variants
210 (polymorphism with a frequency between 0.03 (polymorphism with a frequency above 0.5) was set to 10, while for minor variants
210 (polymorphism with a frequency between 0.03 and 0.49) the number of supporting reads was
211 set to 20.
The nucleotide polymorphisms wer (polymorphism with a frequency between 0.03 and 0.49) the number of supporting reads was
211 set to 20.
212 The nucleotide polymorphisms were evaluated considering their effect on their protein
213 product by SppEff (Galax

211 set to 20.
212 The nuck
213 product b
214 metrics o 212 The nucleotide polymorphisms were evaluated considering their effect on their protein
213 product by SnpEff (Galaxy version 4.5covid) (Cingolani et al., 2012). Finally, the quality
214 metrics of the assemblies were ob product by SnpEff (Galaxy version 4.5covid) (Cingolani et al., 2012). Finally, the quality
214 metrics of the assemblies were obtained with Qualimap BAMQC (Galaxy version 2.2.2)
215 (Okonechnikov et al., 2016).
216 Informa metrics of the assemblies were obtained with Qualimap BAMQC (Galaxy version 2.2.2)
215 (Okonechnikov et al., 2016).
216 Information concerning the worldwide occurrence of specific SARS-CoV-2 genetic
217 Dolymorphisms and f

215 (Okonechnikov et al., 2016).
216 Information concerning the
217 polymorphisms and frequenc
218 216 Information concerning the worldwide occurrence of specific SARS-CoV-2 genetic
217 polymorphisms and frequency was obtained from outbreak.info (Gangavarapu et al., 2023).
218 SARS-CoV-2 lineage assignment 217 polymorphisms and frequency was obtained from outbreak.info (Gangavarapu et al., 2023).
218
229 SARS-CoV-2 lineage assignment
220 To perform SARS-CoV-2 lineage assignment. Frevia pipeline (Karthikevan et al., 2022

218
219
220
221 **SARS-CoV-2 lineage assignment**
220 To perform SARS-CoV-2 lineage
221 currently available at https://gith
222 bioinformatics pineline designed to u To perform SARS-CoV-2 lineage assignment, Freyja pipeline (Karthikeyan et al., 2022),

221 currently available at https://github.com/andersen-lab/Freyja, was used. Freyja is a

222 bioinformatics pipeline designed to estim currently available at https://github.com/andersen-lab/Freyja, was used. Freyja is a
222 bioinformatics pipeline designed to estimate the relative abundance of SARS-CoV-2 lineages
223 in a mixed sample. To assign a lineage bioinformatics pipeline designed to estimate the relative abundance of SARS-CoV-2 lineages

223 in a mixed sample. To assign a lineage to each sample, Freyja stores the single nucleotide

224 polymorphism (SNP) frequencies in a mixed sample. To assign a lineage to each sample, Freyja stores the single nucleotide
224 polymorphism (SNP) frequencies for each of the lineage-defining mutations and recovers
225 relative lineage abundance by solvin polymorphism (SNP) frequencies for each of the lineage-defining mutations and recovers

225 relative lineage abundance by solving a depth-weighted least absolute deviation regression.

226 Note that greater sequencing dept relative lineage abundance by solving a depth-weighted least absolute deviation regression.
226 Note that greater sequencing depth estimate mutation frequencies more accurately, which
227 results in more precise lineage as Note that greater sequencing depth estimate mutation frequencies more accurately, which

227 results in more precise lineage assignments. Freyja assigns SARS-CoV-2 lineages based on

228 the outbreak.info curated lineage m results in more precise lineage assignments. Freyja assigns SARS-CoV-2 lineages based on
228 the outbreak.info curated lineage metadata file that summarizes lineages by World Health
229 Organization (WHO) designation.
230 228 the outbreak.info curated lineage metadata file that summarizes lineages by World Health
229 Organization (WHO) designation.
230 **Data analysis** 229 Organization (WHO) designation.
230
231 **Data analysis**
232 SARS-CoV-2 lineage assignment

232
233 231 **Data analysis**
232 SARS-CoV-2 li
233 obtained from 0 232 SARS-CoV-2 lineage assignment and mutation data derived from clinical surveillance were
233 obtained from GISAID (https://www.gisaid.org/, accessed on the 20th of June 2023) (Elbe and
10 obtained from GISAID (https://www.gisaid.org/, accessed on the 20th of June 2023) (Elbe and
10

Buckland-Merrett, 2017; Shu and McCauley, 2017). Clinical samples from Portugal, with

collection dates ranging between the 19th of April 2022 and the 12th of May 2023,

comprehending the wastewater sample collection p collection dates ranging between the 19th of April 2022 and the 12th collection dates ranging between the 19th of April 2022 and the 12th of May 2023,

236 comprehending the wastewater sample collection period plus two weeks before and

237 afterward, were selected. This dataset was fu comprehending the wastewater sample collection period plus two weeks before and
237 afterward, were selected. This dataset was further filtered to samples isolated in the Health
238 Regions covered by the WWTPs under monit afterward, were selected. This dataset was further filtered to samples isolated in the Health
238 Regions covered by the WWTPs under monitoring in this study (*i.e.*, North, Center, Lisbon
239 and Tagus Valley, and the Alg Regions covered by the WWTPs under monitoring in this study (*i.e.*, North, Center, Lisbon
239 and Tagus Valley, and the Algarve) (Figure S1).
240 Data analysis and visualization was performed with custom Python 3.9.10 (Va

and Tagus Valley, and the Algarve) (Figure S1).
240 Data analysis and visualization was performed v
241 Drake, 2009) and R version 4.1.1 (R Core Te
242 Version 1.4.1 (McKinney, 2010) isoweek versio Data analysis and visualization was performed with custom Python 3.9.10 (Van Rossum and
241 Drake, 2009) and R version 4.1.1 (R Core Team, 2021) scripts. Phyton modules pandas
242 version 1.4.1 (McKinney, 2010) isoweek ver 241 Drake, 2009) and R version 4.1.1 (R Core Team, 2021) scripts. Phyton modules pandas
242 version 1.4.1 (McKinney, 2010) isoweek version 1.3.3, outbreak_data version 1.0.1, and
243 numpy version 1.22.3 (Harris et al., 20 version 1.4.1 (McKinney, 2010) isoweek version 1.3.3, outbreak_data version 1.0.1, and
243 numpy version 1.22.3 (Harris et al., 2020) were used for data manipulation. R packages dplyr
244 version 1.1.2 (Wickham et al., 202 numpy version 1.22.3 (Harris et al., 2020) were used for data manipulation. R packages dplyr
244 version 1.1.2 (Wickham et al., 2023a), ggplot2 version 3.4.2 (Wickham, 2016), gridExtra
245 version 2.3 (Auguie and Antonov, version 1.1.2 (Wickham et al., 2023a), ggplot2 version 3.4.2 (Wickham, 2016), gridExtra
version 2.3 (Auguie and Antonov, 2017) gtable version 0.3.3 (Wickham et al., 2023c), readr
version 2.1.4 (Wickham et al., 2023b) BiocM 247 2023) drawProteins version 1.14.0 (Brennan, 2018), ggforce version 0.4.1 (Pedersen, 2022)
248 vand cowplot version 1.1.1 (Wilke, 2020) were used to create the visualizations in RStudio version 2.1.4 (Wickham et al., 2023b) BiocManager version 1.30.20 (Morgan and Ramos,
247 2023) drawProteins version 1.14.0 (Brennan, 2018), ggforce version 0.4.1 (Pedersen, 2022)
248 and cowplot version 1.1.1 (Wilke, 2020) 247 2023) drawProteins version 1.14.0 (Brennan, 2018), ggforce version 0.4.1 (Pedersen, 2022)
248 and cowplot version 1.1.1 (Wilke, 2020) were used to create the visualizations in RStudio
249 version 1.4.1717 (RStudio Team version 1.4.1717 (RStudio Team, 2021). Spike protein annotations were obtained from
250 UniProt (accession number: P0DTC2; (The UniProt Consortium, 2023)); mutation occurrence
251 per country was retrieved from outbreak.in 251 per country was retrieved from outbreak.info (Gangavarapu et al., 2023) using the R package
252 voutbreakinfo version 0.2.0 (Alkuzweny et al., 2023); the number of sequences made 252 outbreakinfo version 0.2.0 (Alkuzweny et al., 2023); the number of sequences made
253 available per country was retrieved from GISAID (Elbe and Buckland-Merrett, 2017: Shu and 253 available per country was retrieved from GISAID (Elbe and Buckland-Merrett, 2017; Shu and
254 McCauley. 2017): and the Simpson evenness index was calculated using R package abdiv outbreakinfo version 0.2.0 (Alkuzweny et al., 2023); the number of sequences made
available per country was retrieved from GISAID (Elbe and Buckland-Merrett, 2017; Shu and
McCauley, 2017); and the Simpson evenness index wa 253 available per country was retrieved from GISAID (Elbe and Buckland-Merrett, 2017; Shu and
254 McCauley, 2017); and the Simpson evenness index was calculated using R package abdiv
255 version 0.2.0 (Bittinger, 2020). 254 McCauley, 2017); and the Simpson evenness index was calculated using R package abdiv
255 version 0.2.0 (Bittinger, 2020). 255 version 0.2.0 (Bittinger, 2020).

256 **RESULTS**
257 **The adapt
258 captures ti**
259 All the 133

The adaptive combination of RT-PCR allelic discrimination assays successfully

258 captures the co-occurrence and progression of the main Omicron sub-lineages

259 All the 1339 wastewater samples under focus in this study **captures the co-occurrence and progression of the main Omicron sub-lineages**
259 All the 1339 wastewater samples under focus in this study were tested for the pres
260 specific mutations associated to one or several Omicr All the 1339 wastewater samples under focus in this study were tested for the presence of
260 specific mutations associated to one or several Omicron sub-lineages. Given the fast
261 evolution of Omicron sub-lineages, the specific mutations associated to one or several Omicron sub-lineages. Given the fast
261 evolution of Omicron sub-lineages, the panel of applied genotyping assays was regularly
262 updated (Figure S2) throughout the sampli evolution of Omicron sub-lineages, the panel of applied genotyping assays was regularly

262 updated (Figure S2) throughout the sampling period to discriminate new sub-lineages. This

263 meant adding new assays targeting updated (Figure S2) throughout the sampling period to discriminate new sub-lineages. This
263 meant adding new assays targeting diagnostic mutations of new sub-lineages and halting
264 assays that no longer had discriminat meant adding new assays targeting diagnostic mutations of new sub-lineages and halting
264 assays that no longer had discrimination power over the sub-lineages circulating in that
265 period. These decisions were informed assays that no longer had discrimination power over the sub-lineages circulating in that

265 period. These decisions were informed both by the results that were being obtained weekly,

266 as well as by the clinical surve period. These decisions were informed both by the results that were being obtained weekly,
266 as well as by the clinical surveillance data made publicly available by the Directorate-General
267 of Health (DGS) and the Nat

as well as by the clinical surveillance data made publicly available by the Directorate-General
267 of Health (DGS) and the National Institute of Health Doutor Ricardo Jorge (INSA, 2021).
268 At sampling starting point, fo of Health (DGS) and the National Institute of Health Doutor Ricardo Jorge (INSA, 2021).
268 At sampling starting point, four genotyping assays were applied. The genotyping assay
269 detected a signature mutation of the Omi 268 At sampling starting point, four genotyping assays were applied. The genotyping assay that
269 detected a signature mutation of the Omicron VOC (*i.e.*, S:G339D) was selected to assess
270 the circulation of older VOCs detected a signature mutation of the Omicron VOC (*i.e.*, S:G339D) was selected to assess
270 the circulation of older VOCs that possess the wild-type allele. Note that at the beginning of
271 the sampling period, Omicron the circulation of older VOCs that possess the wild-type allele. Note that at the beginning of
271 the sampling period, Omicron was already the dominant VOC. With the exception of ISO
272 week 24, the mutant allele was exc 271 the sampling period, Omicron was already the dominant VOC. With the exception of ISO
272 week 24, the mutant allele was exclusively detected until September 2022 (ISO week 38),
273 from which point both alleles were re week 24, the mutant allele was exclusively detected until September 2022 (ISO week 38),
273 from which point both alleles were regularly identified (Figure S3). Clinical surveillance data
274 for all analyzed regions (Figu from which point both alleles were regularly identified (Figure S3). Clinical surveillance data
274 for all analyzed regions (Figure 1A) showed that, at that time point, the resurgence of older
275 VOCs was not being obser 274 for all analyzed regions (Figure 1A) showed that, at that time point, the resurgence of older
275 VOCs was not being observed, but instead detection of the wild type allele corresponded to
276 the emergence of Omicron VOCs was not being observed, but instead detection of the wild type allele corresponded to
276 the emergence of Omicron sub-lineages without this mutation, among them the recombinant
277 sub-lineages of CH and XBB (named h the emergence of Omicron sub-lineages without this mutation, among them the recombinant
277 sub-lineages of CH and XBB (named hereafter CH.X and XBB.X). Given that this mutation
278 was no longer a signature mutation for t sub-lineages of CH and XBB (named hereafter CH.X and XBB.X). Given that this mutation
278 was no longer a signature mutation for the Omicron VOC, we suspended the application of
279 this assay in the beginning of November was no longer a signature mutation for the Omicron VOC, we suspended the application of

279 this assay in the beginning of November 2022 (week 45).

280 Another assay applied at the beginning of our sampling period was ab

this assay in the beginning of November 2022 (week 45).
280 Another assay applied at the beginning of our samplin
281 Signature mutation of the Omicron BA.1 lineage and its day
282 Figure S2). However, we have only applied 280 Another assay applied at the beginning of our sampling period was able to identify the
281 signature mutation of the Omicron BA.1 lineage and its daughter lineages (BA.1.X; S:T475K;
282 Figure S2). However, we have onl 281 signature mutation of the Omicron BA.1 lineage and its daughter lineages (BA.1.X; S:T475K;
282 Figure S2). However, we have only applied this assay during the first two weeks of the
283 sampling period (weeks 18 and 19 282 Figure S2). However, we have only applied this assay during the first two weeks of the
283 sampling period (weeks 18 and 19) given that the mutant allele was never amplified in any
12 283 sampling period (weeks 18 and 19) given that the mutant allele was never amplified in any
12

284 sample (Figure S3). This observation supported the hypothesis that BA.1.X sub-lineages
285 were no longer circulating in the analyzed communities, which agreed with the clinical
286 epidemiological data (Figure 1A) and were no longer circulating in the analyzed communities, which agreed with the clinical
286 epidemiological data (Figure 1A) and led to the early exclusion of this assay from the panel.
287 Between May 2022 (week 18) and No epidemiological data (Figure 1A) and led to the early exclusion of this assay from the panel.
287 Between May 2022 (week 18) and November 2022 (week 48) the genotyping assay that
288 identifies the S:Q493R mutation present 287 Between May 2022 (week 18) and November 2022 (week 48) the genotyping assay that
288 identifies the S:Q493R mutation present in BA.1.X, BA.2.X and BA.3.X Omicron sub-lineages
289 was applied (Figure S2). Knowing that B identifies the S:Q493R mutation present in BA.1.X, BA.2.X and BA.3.X Omicron sub-lineages
was applied (Figure S2). Knowing that BA.3.X had only been detected twice in Portugal
through genome sequencing and before the start was applied (Figure S2). Knowing that BA.3.X had only been detected twice in Portugal
290 through genome sequencing and before the start of our sampling period, and also being
291 aware that BA.1.X was being reported from 290 through genome sequencing and before the start of our sampling period, and also being
291 aware that BA.1.X was being reported from week 16 in percentages bellow 1%, the
292 identification of the mutant allele S:Q493R 291 aware that BA.1.X was being reported from week 16 in percentages bellow 1%, the
292 identification of the mutant allele S:Q493R was presumed indicative of BA.2.X circulation.
293 Between ISO weeks 18 and 29, the clinic identification of the mutant allele S:Q493R was presumed indicative of BA.2.X circulation.
293 Between ISO weeks 18 and 29, the clinical data shows the substitution of BA.2.X by BA.5.X
294 (Figure 1A). BA.2.X sub-lineages Between ISO weeks 18 and 29, the clinical data shows the substitution of BA.2.X by BA.5.X
294 (Figure 1A). BA.2.X sub-lineages were dominant in the clinical data until week 19,
295 representing over 50% of the available se 294 (Figure 1A). BA.2.X sub-lineages were dominant in the clinical data until week 19,
295 representing over 50% of the available sequences. In wastewater samples, the mutant allele
296 of S:Q493R was detected in over 50% representing over 50% of the available sequences. In wastewater samples, the mutant allele
296 of S:Q493R was detected in over 50% of samples for five weeks longer (*i.e.*, until week 24)
297 but also with a decreasing ten 296 of S:Q493R was detected in over 50% of samples for five weeks longer (*i.e.*, until week 24)
297 but also with a decreasing tendency (Figure S3). Interpretation of results for samples with
298 amplification of the muta but also with a decreasing tendency (Figure S3). Interpretation of results for samples with

298 amplification of the mutant allele only, without amplification of the wild type allele, was

299 translated as the presumable amplification of the mutant allele only, without amplification of the wild type allele, was

299 translated as the presumable presence of 100% BA.2.X sub-lineages in the wastewater

300 samples. Detection of this mutant al translated as the presumable presence of 100% BA.2.X sub-lineages in the wastewater
200 samples. Detection of this mutant allele stopped at week 20, after which amplification of both
201 alleles was obtained, suggesting th samples. Detection of this mutant allele stopped at week 20, after which amplification of both
301 alleles was obtained, suggesting the coexistence of both BA.2.X and BA.5.X sub-lineages in
302 the same sample. Similar re alleles was obtained, suggesting the coexistence of both BA.2.X and BA.5.X sub-lineages in
302 the same sample. Similar results were observed at regional level, with the mutant allele of
303 S:Q493R amplified in over 50% o the same sample. Similar results were observed at regional level, with the mutant allele of
303 S:Q493R amplified in over 50% of samples until week 23 in Algarve, and until week 24 in
304 North, Center and, Lisbon and Tagu 303 S:Q493R amplified in over 50% of samples until week 23 in Algarve, and until week 24 in
304 North, Center and, Lisbon and Tagus Valley (LTV) regions (Figure S4). The identification of
305 samples only with the amplific 304 North, Center and, Lisbon and Tagus Valley (LTV) regions (Figure S4). The identification of
305 samples only with the amplification of the mutant allele stopped at week 19 in the North,
306 Center and LTV regions, and samples only with the amplification of the mutant allele stopped at week 19 in the North,
306 Center and LTV regions, and at week 20 at Algarve. Despite the similarities, the increase in
307 detection of the wild type alle 306 Center and LTV regions, and at week 20 at Algarve. Despite the similarities, the increase in
307 detection of the wild type allele, and consequently the decrease of BA.2.X detection, was
308 faster in the LTV region, f detection of the wild type allele, and consequently the decrease of BA.2.X detection, was
308 faster in the LTV region, followed by Algarve, North and Center regions (Figure S4).
309 The mutation S:L452R is present in BA.4

faster in the LTV region, followed by Algarve, North and Center regions (Figure S4).
309 The mutation S:L452R is present in BA.4.X, BA.5.X and BA.2.35, and was also app
310 the beginning of our sampling period and until we 309 The mutation S:L452R is present in BA.4.X, BA.5.X and BA.2.35, and was also applied from
310 the beginning of our sampling period and until week 29. Since the percentage of BA.4.X
311 sequences isolated until week 29 w 310 the beginning of our sampling period and until week 29. Since the percentage of BA.4.X
311 sequences isolated until week 29 was residual, the presence of the mutant allele was taken
13 311 sequences isolated until week 29 was residual, the presence of the mutant allele was taken

as an indication of the presence of BA.5.X or BA.2.35 sub-lineages. The combination of
313 results from genotyping assays S:Q493R and S:L452R resolved the ambiguity of the assay
314 for mutation S:Q493R in lineage assignme results from genotyping assays S:Q493R and S:L452R resolved the ambiguity of the assay
314 for mutation S:Q493R in lineage assignment and allowed detecting the presence of BA.2.35
315 sub-lineage. Based on this, sub-lineag for mutation S:Q493R in lineage assignment and allowed detecting the presence of BA.2.35
315 sub-lineage. Based on this, sub-lineage BA.2.35 was presumably present in Portugal at least
316 until week 24.
317 At week 29, tw sub-lineage. Based on this, sub-lineage BA.2.35 was presumably present in Portugal at least
316 until week 24.
317 At week 29, two new assays were added (Figure S2): the genotyping assay ORF7b:L11F,
318 which identifies a

316 until week 24.
317 At week 29, tv
318 which identifie:
319 2022 (week 52 317 At week 29, two new assays were added (Figure S2): the genotyping assay ORF7b:L11F,
which identifies a signature mutation of BA.4.X sub-lineage, that was applied until the end of
2022 (week 52); and the genotyping assa which identifies a signature mutation of BA.4.X sub-lineage, that was applied until the end of
319 2022 (week 52); and the genotyping assay M:D3N, which identifies the signature mutation of
320 BA.5.X, that was applied unt 2022 (week 52); and the genotyping assay M:D3N, which identifies the signature mutation of
320 BA.5.X, that was applied until Abril 2023 (week 17).
321 Concerning BA.4.X sub-lineage, none of the analyzed samples revealed t

BA.5.X, that was applied until Abril 2023 (week 17).
321 Concerning BA.4.X sub-lineage, none of the a
322 amplification of the mutant allele, indicating that the
323 all times with BA.5 X From week 29 until week 34 321 Concerning BA.4.X sub-lineage, none of the analyzed samples revealed the unique
322 amplification of the mutant allele, indicating that the presence of BA.4.X was concomitant at
323 all times with BA.5.X. From week 29 amplification of the mutant allele, indicating that the presence of BA.4.X was concomitant at
323 all times with BA.5.X. From week 29 until week 34, the signature mutation of BA.4.X was
324 identified in most samples. At t all times with BA.5.X. From week 29 until week 34, the signature mutation of BA.4.X was
324 identified in most samples. At the national scale, the last reported detection of this lineage on
325 clinically derived sequences identified in most samples. At the national scale, the last reported detection of this lineage on
325 clinically derived sequences is dated from week 48, while in wastewater samples the mutant
326 allele was amplified unti clinically derived sequences is dated from week 48, while in wastewater samples the mutant
326 allele was amplified until week 49. Considering the regional stratification, the identification of
327 BA.4.X in wastewater con allele was amplified until week 49. Considering the regional stratification, the identification of

327 BA.4.X in wastewater continued to be reported later in time when comparing with clinical

328 data (Figures 1, S4 and BA.4.X in wastewater continued to be reported later in time when comparing with clinical
328 data (Figures 1, S4 and S5), except for the Center region. Specifically, at the Algarve, BA.4.X
329 was last identified in wastew data (Figures 1, S4 and S5), except for the Center region. Specifically, at the Algarve, BA.4.X
329 was last identified in wastewater at week 46, while in clinical data was at week 40; at LTV it
330 was last reported in wa was last identified in wastewater at week 46, while in clinical data was at week 40; at LTV it
330 was last reported in wastewater at week 49, while at clinical data was at week 43; at North, it
331 was detected up to week was last reported in wastewater at week 49, while at clinical data was at week 43; at North, it
331 was detected up to week 45 in wastewater and at week 43 in clinical data (Figure S5). The
332 center region clinical data was detected up to week 45 in wastewater and at week 43 in clinical data (Figure S5). The
332 center region clinical data reported BA.4.X until week 48, while in wastewater it was detected
333 up until week 46. Since the m center region clinical data reported BA.4.X until week 48, while in wastewater it was detected
333 up until week 46. Since the mutant allele was not detected at wastewater samples in the last
334 three weeks of 2022, we su up until week 46. Since the mutant allele was not detected at wastewater samples in the last
334 three weeks of 2022, we suspended the implementation of the genotyping assay
335 ORF7b:L11F in the end of 2022. three weeks of 2022, we suspended the implementation of the genotyping assay
335 ORF7b:L11F in the end of 2022.
336 Regarding BA.5.X, the mutant allele (*i.e.*, M:D3N) was identified in all samples recovered
337 between we

335 ORF7b:L11F in the end of 2022.
336 Regarding BA.5.X, the mutant a
337 between week 29 of 2022 and
338 circulation of BA.5.X. This is in 338 Circulation of BA.5.X. This is in agreement with the clinical data that shows BA.5.X with an
1939 Tincreased and dominant tendency until the end of 2022, when XBB.X started increasing their 337 between week 29 of 2022 and week 17 of 2023 (Figure S3), attesting the uninterrupted
338 circulation of BA.5.X. This is in agreement with the clinical data that shows BA.5.X with an
339 increased and dominant tendency 338 circulation of BA.5.X. This is in agreement with the clinical data that shows BA.5.X with an
339 increased and dominant tendency until the end of 2022, when XBB.X started increasing their
14 339 increased and dominant tendency until the end of 2022, when XBB.X started increasing their

340 frequency (Figure 1). At the regional level, the scenario is similar, with the mutant allele
341 amplified in over 50% of samples until week 13 of 2023 at North region, until week 12 at
342 national level and at LTV re 341 amplified in over 50% of samples until week 13 of 2023 at North region, until week 12 at
342 national level and at LTV region, until week 10 at Center region, and until week 9 at Algarve
343 region (Figure S4). This sh national level and at LTV region, until week 10 at Center region, and until week 9 at Algarve

1343 region (Figure S4). This shows that the substitution of BA.5.X by XBB.X was faster at

1344 Algarve region, followed by Ce region (Figure S4). This shows that the substitution of BA.5.X by XBB.X was faster at
344 Algarve region, followed by Center, then LTV and later in the North region.
345 Figure 1B presents a comprehensive summary of the wa

Algarve region, followed by Center, then LTV and later in the North region.
345 Figure 1B presents a comprehensive summary of the wastewater data,
346 Comparison between the results from RT-PCR genotyping assays and
347 Dr Figure 1B presents a comprehensive summary of the wastewater data, enabling the easy
346 comparison between the results from RT-PCR genotyping assays and the clinical data
347 presented in Figure 1A. The samples are groupe comparison between the results from RT-PCR genotyping assays and the clinical data
347 presented in Figure 1A. The samples are grouped by week, and the categories represent all
348 the sub-lineages found in each sample. No presented in Figure 1A. The samples are grouped by week, and the categories represent all
the sub-lineages found in each sample. Note that, for 21 samples, the allele discrimination
analysis was inconclusive due to lack of the sub-lineages found in each sample. Note that, for 21 samples, the allele discrimination
349 analysis was inconclusive due to lack of amplification, which might be due to the complex
350 nature of wastewater samples tha 350 nature of wastewater samples that can contain PCR inhibitors and other contaminants.
351 Another possible reason for the lack of amplification in these samples concerns the
352 sensitivity of the assays. In fact, the m nature of wastewater samples that can contain PCR inhibitors and other contaminants.
351 Another possible reason for the lack of amplification in these samples concerns the
352 sensitivity of the assays. In fact, the manuf 351 Another possible reason for the lack of amplification in these samples concerns the
352 sensitivity of the assays. In fact, the manufacturer recommends the assays to be applied to
353 samples whose Ct was inferior to 3 sensitivity of the assays. In fact, the manufacturer recommends the assays to be applied to
353 samples whose Ct was inferior to 30 in the RT-qPCR for SARS-CoV-2 identification, which
354 was not the case for any of these stamples whose Ct was inferior to 30 in the RT-qPCR for SARS-CoV-2 identification, which
354 was not the case for any of these samples.
355 354 was not the case for any of these samples.
355

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297774;](https://doi.org/10.1101/2023.10.30.23297774) this version posted October 31, 2023. The copyright holder for this preprint

356
357
358
359
360
361 **Figure 1: Lineage frequency evolution. A.** Lineage assignment of sequences derived from clinical
358 genomic surveillance. The samples were collected in Portugal (in North, Center, Lisbon and Tagus
359 Valley, and Algarve genomic surveillance. The samples were collected in Portugal (in North, Center, Lisbon and Tagus

359 Valley, and Algarve Health Regions) between ISO week 16 of year 2022 and ISO week 19 of year

360 2023. Lineages were gr 2023. Lineages were grouped with all descendant lineages of the five major circulating sub-lineages
361 (BA.1, BA.2, BA.4, BA.5 and XBB) grouped into a single category. The remaining (minor) lineages
362 were grouped into real-time PCR diagnostic data (allelic discrimination assays). Based on the tested alleles, the samples
364 were grouped into 14 categories. Most of the categories group samples in which multiple major
365 circulating line (BA.1, BA.2, BA.4, BA.5 and XBB) grouped into a single category. The remaining (minor) lineages

362 were grouped into a single category (Other). **B.** Lineage assignments in WWTP samples based on

363 real-time PCR diagnos were grouped into a single category (Other). **B.** Lineage assignments in WWTP samples based on real-time PCR diagnostic data (allelic discrimination assays). Based on the tested alleles, the samples were grouped into 14 ca real-time PCR diagnostic data (allelic discrimination assays). Based on the tested alleles, the samples
364 were grouped into 14 categories. Most of the categories group samples in which multiple major
365 circulating line were grouped into 14 categories. Most of the categories group samples in which multiple major

365 circulating lineages were detected. The forward slash indicates that the test cannot distinguish

366 between the two linea circulating lineages were detected. The forward slash indicates that the test cannot distinguish
366 between the two lineages. In a small number of samples, amplification was not obtained in all
367 necessary real-time PCR between the two lineages. In a small number of samples, amplification was not obtained in all
367 necessary real-time PCR assays and hence they were grouped in the category "Inconclusive".
368 Samples not tested were group necessary real-time PCR assays and hence they were grouped in the category "Inconclusive".

368 Samples not tested were grouped in the Not Determined (ND) category. **C.** Lineage assignments in

369 WWTP samples based on se Samples not tested were grouped in the Not Determined (ND) category. **C.** Lineage assignments in
369 WWTP samples based on sequencing data. The data was grouped in the same categories as those in
370 panel A for convenienc WWTP samples based on sequencing data. The data was grouped in the same categories as those in
370 panel A for convenience of comparison. **D.** Average horizontal S gene sequencing coverage and
371 number of sequenced sampl panel A for convenience of comparison. **D.** Average horizontal S gene sequencing coverage and
371 number of sequenced samples per week (referring to the data presented in panel C). Vertical blue
372 bars represent the aver 371 number of sequenced samples per week (referring to the data presented in panel C). Vertical blue
372 bars represent the average horizontal coverage of that week's samples, and red dots represent the
373 number of seque 372 bars represent the average horizontal coverage of that week's samples, and red dots represent the
373 number of sequenced samples on that week. Note that ISO weeks 16 and 17 of 2022 and ISO weeks
374 18 and 19 of 2023 373 number of sequenced samples on that week. Note that ISO weeks 16 and 17 of 2022 and ISO weeks
374 18 and 19 of 2023 were out of our wastewater sampling period. On ISO week 35 of 2022, there was
375 no sampling at all, 374 18 and 19 of 2023 were out of our wastewater sampling period. On ISO week 35 of 2022, there was
375 no sampling at all, and on ISO weeks 48 of 2022 and 01 of 2023, no samples were sequenced due to
376 the low quality o 375 no sampling at all, and on ISO weeks 48 of 2022 and 01 of 2023, no samples were sequenced due to
376 the low quality of the samples' RNA.
377 376 the low quality of the samples' RNA.
377
378

377
378

S gene sequencing exhibits high sensitivity to sample quality variations
380 From the initial pool of 1339 samples, 332 were selected for S gene sequencing based on
381 specific criteria: RNA concentration above 20 ng/µl specific criteria: RNA concentration above 20 ng/µl, Ct values of the RT-qPCR for SARS-
382 CoV-2 detection below 36, and the inclusion of two samples per month per WWTP. Given
383 the pivotal role of the viral Spike prote 383 the pivotal role of the viral Spike protein in the infectious process, mediating viral entry into
384 host cells (Jackson et al.. 2022) and its significance in generating new VOCs with heightened 382 CoV-2 detection below 36, and the inclusion of two samples per month per WWTP. Given
383 the pivotal role of the viral Spike protein in the infectious process, mediating viral entry into
384 host cells (Jackson et al., the pivotal role of the viral Spike protein in the infectious process, mediating viral entry into

1884 host cells (Jackson et al., 2022) and its significance in generating new VOCs with heightened

1885 transmissibility (1384 host cells (Jackson et al., 2022) and its significance in generating new VOCs with heightened
1385 transmissibility (Markov et al., 2023), targeted sequencing of the S gene was carried out.
1386 The resulting data und

transmissibility (Markov et al., 2023), targeted sequencing of the S gene was carried out.
386 The resulting data underwent meticulous analysis to identify diagnostic mutations,
387 frequency mutations, and even new mutati 386 The resulting data underwent meticulous analysis to identify diagnostic mutations, low-
387 frequency mutations, and even new mutations, along with lineage assignment, facilitating
388 direct comparison with data from 387 frequency mutations, and even new mutations, along with lineage assignment, facilitating
388 direct comparison with data from clinical surveillance and the data generated in parallel via
389 the RT-PCR genotyping assay direct comparison with data from clinical surveillance and the data generated in parallel via

389 the RT-PCR genotyping assays.

390 Throughout the analyses, it became evident that the horizontal coverage of the S gene

3

389 the RT-PCR genotyping assays.
390 Throughout the analyses, it been
391 varied considerably, significantly
392 (compare Figure 2A with Figure 391 varied considerably, significantly impacting the number of mutations detected per sample
392 (compare Figure 2A with Figure 2C). On average, the S gene's horizontal coverage by at
393 least 10 reads was 50.2 ± 29.5 % 391 varied considerably, significantly impacting the number of mutations detected per sample
392 (compare Figure 2A with Figure 2C). On average, the S gene's horizontal coverage by at
393 least 10 reads was $50.2 \pm 29.5\%$ 392 (compare Figure 2A with Figure 2C). On average, the S gene's horizontal coverage by at
393 least 10 reads was $50.2 \pm 29.5\%$, with 31% of the samples (n = 103) showing coverages
394 above 70%. However, during specifi 393 least 10 reads was 50.2 ± 29.5 %, with 31% of the samples (n = 103) showing coverages
394 above 70%. However, during specific time points, particularly in weeks encompassing
395 October and November 2022, and January 394 above 70%. However, during specific time points, particularly in weeks encompassing
395 October and November 2022, and January, March, and April 2023, the horizontal coverage
396 dropped to an average of less than 25% 395 October and November 2022, and January, March, and April 2023, the horizontal coverage
396 dropped to an average of less than 25% of the S gene (Figure 2C). Lower coverages also
397 coincided with higher values of the dropped to an average of less than 25% of the S gene (Figure 2C). Lower coverages also
coincided with higher values of the Simpson Evenness Index. A Simpson Evenness Index
close to 1 indicates that all mutations have equal coincided with higher values of the Simpson Evenness Index. A Simpson Evenness Index
close to 1 indicates that all mutations have equal abundances in the set of samples of that
week, while a value close to 0 suggests the s close to 1 indicates that all mutations have equal abundances in the set of samples of that
399 week, while a value close to 0 suggests the sample set is dominated by only a few highly
300 prevalent mutations. In our datas week, while a value close to 0 suggests the sample set is dominated by only a few highly

400 prevalent mutations. In our dataset, we observed that lower horizontal coverage of the S

401 gene led to the detection of fewer prevalent mutations. In our dataset, we observed that lower horizontal coverage of the S
401 gene led to the detection of fewer mutations per sample, all with more comparable
402 abundances in the sample set. On the contra gene led to the detection of fewer mutations per sample, all with more comparable
402 abundances in the sample set. On the contrary, higher horizontal coverage of the S gene
403 resulted in the detection of a greater numbe resulted in the detection of a greater number of mutations per sample, with a few mutations
404 being over-represented in the samples set. This observation suggests that, in some samples
405 with low horizontal coverage of resulted in the detection of a greater number of mutations per sample, with a few mutations
404 being over-represented in the samples set. This observation suggests that, in some samples
405 with low horizontal coverage of 404 being over-represented in the samples set. This observation suggests that, in some samples
405 with low horizontal coverage of the S gene, we might not have been able to capture the full
406 scope of mutations present. with low horizontal coverage of the S gene, we might not have been able to capture the full
406 scope of mutations present.
17 406 scope of mutations present.

The scope of mutations present.

We then attempted to correlate the observed low horizontal coverage of the S gene,
408 particularly evident in certain weeks (e.g., weeks 39 to 47; Figure 2C), with various
409 wastewater sample parameters such as the pH, particularly evident in certain weeks (*e.g.*, weeks 39 to 47; Figure 2C), with various
wastewater sample parameters such as the pH, biological oxygen demand, daily
410 temperature, daily rainfall, and nitrogen and phospho wastewater sample parameters such as the pH, biological oxygen demand, daily
410 temperature, daily rainfall, and nitrogen and phosphorus concentrations. However, no
411 significant correlations were found that could expla temperature, daily rainfall, and nitrogen and phosphorus concentrations. However, no
significant correlations were found that could explain the observed low S gene coverage
(data not shown). Similarly, no correlations were significant correlations were found that could explain the observed low S gene coverage

412 (data not shown). Similarly, no correlations were observed with RNA concentration or viral

413 load, indicating that other facto (data not shown). Similarly, no correlations were observed with RNA concentration or viral
1413 Ioad, indicating that other factors might be at play, such as RNA integrity or the presence of
1414 PCR inhibitors commonly fo load, indicating that other factors might be at play, such as RNA integrity or the presence of
414 PCR inhibitors commonly found in wastewater samples (Amman et al., 2022; Baaijens et al.,
415 2021; Silva et al., 2022), de PCR inhibitors commonly found in wastewater samples (Amman et al., 2022; Baaijens et al.,
2021; Silva et al., 2022), despite our additional RNA purification steps. These factors can
adversely affect the sequencing process, 2021; Silva et al., 2022), despite our additional RNA purification steps. These factors can
adversely affect the sequencing process, leading to limited sequence coverage and
subsequently restricting downstream analysis.
41 416 adversely affect the sequencing process, leading to limited sequence coverage and
417 subsequently restricting downstream analysis.
418 417 subsequently restricting downstream analysis.

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297774;](https://doi.org/10.1101/2023.10.30.23297774) this version posted October 31, 2023. The copyright holder for this preprint

419
420
421
422
423
424 Figure 2: Number and type of S gene mutations. A. Number of S gene mutations by week. B. Box
421 plot of the distribution of the Simpson Evenness Index calculated for each analyzed sample and
422 represented by week. C. Di plot of the distribution of the Simpson Evenness Index calculated for each analyzed sample and

422 represented by week. C. Distribution of the average horizontal S gene sequencing coverage

423 determined for each sample extinguion of the average horizontal S gene sequencing coverage
423 determined for each sample and represented by week. Horizontal coverage of S gene of at least 10X
424 is represented in percentage. **D.** Pie chart showing determined for each sample and represented by week. Horizontal coverage of S gene of at least 10X
424 is represented in percentage. **D.** Pie chart showing the relative proportion of each type of mutation
425 detected in th 424 is represented in percentage. **D.** Pie chart showing the relative proportion of each type of mutation detected in the samples. STOP refers to a mutation that generates a premature stop codon. **E.** Each detected mutatio detected in the samples. STOP refers to a mutation that generates a premature stop codon. **E.** Each
426 detected mutation was assigned as being associated with one or multiple lineages based on
427 occurrence. Two novel un 426 detected mutation was assigned as being associated with one or multiple lineages based on
427 occurrence. Two novel unique mutations were not assigned to any lineage ("No sequences").
19 427 occurrence. Two novel unique mutations were not assigned to any lineage ("No sequences").

428

429
430
431 ---
430
431
432

The majority of detected mutations are missense SNPs associated with the Omicron
431 **VOC**
432 In the 332 sequenced samples, a total of 7168 SNPs and 278 insertions/deletions (INDELs)
433 were discriminated within the S ge 431 **VOC**
432 In the
433 were
434 refere were discriminated within the S gene over time when compared to the SARS-CoV-2
134 reference genome (NC_045512.2). On average, each sample registered 22 \pm 16
135 polymorphisms (comprising both SNPs and INDELs). Among t were discriminated within the S gene over time when compared to the SARS-CoV-2
434 reference genome (NC_045512.2). On average, each sample registered 22 \pm 16
435 polymorphisms (comprising both SNPs and INDELs). Among t reference genome (NC_045512.2). On average, each sample registered 22 ± 16
435 polymorphisms (comprising both SNPs and INDELs). Among these, the majority were
436 missense SNPs (89.8%), followed by synonymous SNPs (5.9% missense SNPs (89.8%), followed by synonymous SNPs (5.9%), INDELs (3.7%), and the

437 introduction of premature STOP codons (0.6%) (Figure 2D).

438 The identified missense SNPs were classified based on their occurrence w

438 The identified missense SNPs were classified based on their occurrence within various
439 VOCs. Some missense SNPs were associated with one or multiple VOCs. while others were introduction of premature STOP codons (0.6%) (Figure 2D).
438 The identified missense SNPs were classified based on
439 VOCs. Some missense SNPs were associated with one or r
440 not specifically linked to any known VOC or The identified missense SNPs were classified based on their occurrence within various
439 VOCs. Some missense SNPs were associated with one or multiple VOCs, while others were
440 not specifically linked to any known VOC o not specifically linked to any known VOC or had never been previously reported (Figure 2E).
441 As expected, most missense SNPs were associated with the Omicron VOC (Figure 2E),
442 which was the dominant VOC in our sampli not specifically linked to any known VOC or had never been previously reported (Figure 2E).
441 As expected, most missense SNPs were associated with the Omicron VOC (Figure 2E),
442 which was the dominant VOC in our sampli As expected, most missense SNPs were associated with the Omicron VOC (Figure 2E),
which was the dominant VOC in our sampling period. In addition, mutations associated with
older VOCs such as Alpha, Delta, Beta, and Gamma w older VOCs such as Alpha, Delta, Beta, and Gamma were also sporadically observed in our
samples (Figure 2E). Clinical-derived reports have Delta accounting for 0.01% of worldwide
recovered SARS-CoV-2 sequences during our s older VOCs such as Alpha, Delta, Beta, and Gamma were also sporadically observed in our
samples (Figure 2E). Clinical-derived reports have Delta accounting for 0.01% of worldwide
recovered SARS-CoV-2 sequences during our s samples (Figure 2E). Clinical-derived reports have Delta accounting for 0.01% of worldwide

recovered SARS-CoV-2 sequences during our sampling period (source: GISAID on the 1st of

446 August 2023). Mutations associated recovered SARS-CoV-2 sequences during our sampling period (source: GISAID on the 1st August 2023). Mutations associated with other VOCs, excluding Delta and Omicron, were
sporadic, likely due to their very low prevalence, collectively representing only 0.002% of
worldwide recovered sequences in our samplin 448 worldwide recovered sequences in our sampling period. Note that in the clinical surveillance
449 data, other VOCs were never detected, which is not surprising given their residual circulation. sporadic, likely due to their very low prevalence, collectively representing only 0.002% of
worldwide recovered sequences in our sampling period. Note that in the clinical surveillance
data, other VOCs were never detected, worldwide recovered sequences in our sampling period. Note that in the clinical surveillance
data, other VOCs were never detected, which is not surprising given their residual circulation.
450
Frequency and coverage constr data, other VOCs were never detected, which is not surprising given their residual circulation.
450
Trequency and coverage constrain SNP detection in wastewater samples
Me proceeded to compare the missense SNPs identified

450
451
452
453 Frequency and coverage constrain SNP detection in wastewater samples
452 We proceeded to compare the missense SNPs identified in our wastewater samples with
453 those detected in clinical samples obtained during the same t We proceeded to compare the missense SNPs identified in our wastewater samples with

453 those detected in clinical samples obtained during the same time period. The aim was to

454 assess the performance of our wastewater those detected in clinical samples obtained during the same time period. The aim was to
454 assess the performance of our wastewater analyses compared to clinical genomic
455 surveillance. In this analysis, we focused on m 454 assess the performance of our wastewater analyses compared to clinical genomic
455 surveillance. In this analysis, we focused on missense SNPs and found that only 10.7% of
20 455 surveillance. In this analysis, we focused on missense SNPs and found that only 10.7% of
20
20

them were identified in both sample types - clinical and wastewater (Figure 3A). Most

1457 missense SNPs (61.8%) were exclusively found in clinical-derived sequences, while 27.4%

1458 were exclusively detected in wastewa missense SNPs (61.8%) were exclusively found in clinical-derived sequences, while 27.4%
were exclusively detected in wastewater samples (Figure 3A).
Upon closer examination of this distribution, we observed that in weeks w

were exclusively detected in wastewater samples (Figure 3A).
459 Upon closer examination of this distribution, we observed tha
460 higher horizontal coverage of the S gene, the percentage of
161 clinical samples decreased Upon closer examination of this distribution, we observed that in weeks where we obtained

460 higher horizontal coverage of the S gene, the percentage of mutations exclusively found in

461 clinical samples decreased (Fig

higher horizontal coverage of the S gene, the percentage of mutations exclusively found in

1461 clinical samples decreased (Figure 3B).

1462 We went deeper into our analysis by examining the consistency of detection of m clinical samples decreased (Figure 3B).
462 We went deeper into our analysis by 6
463 mutations present both in clinical and v
464 throughout the sampling period and act We went deeper into our analysis by examining the consistency of detection of missense

463 mutations present both in clinical and wastewater samples, aiming to identify any patterns

464 throughout the sampling period and mutations present both in clinical and wastewater samples, aiming to identify any patterns

464 throughout the sampling period and across the full extent of the Spike protein (Figure 3C).

465 We observed three distinct se 464 throughout the sampling period and across the full extent of the Spike protein (Figure 3C).
465 We observed three distinct sets of mutations. Firstly, there were mutations that occurred
466 sporadically in both sample We observed three distinct sets of mutations. Firstly, there were mutations that occurred
466 sporadically in both sample types, such as D228G, K417T, and S929T. These mutations are
467 of low prevalence, both in Portugal 468 2023, source: outbreak.info). Therefore, their detection in wastewater samples is also
469 sporadic and not simultaneous with clinical detection. Secondly there were mutations such of low prevalence, both in Portugal and worldwide (below 1% prevalence as of August 1 $^{\rm st}$ of low prevalence, both in Portugal and worldwide (below 1% prevalence as of August 1st,
2023, source: outbreak.info). Therefore, their detection in wastewater samples is also
469 sporadic and not simultaneous with clini 2023, source: outbreak.info). Therefore, their detection in wastewater samples is also
sporadic and not simultaneous with clinical detection. Secondly, there were mutations, such
as S371F, N501Y, and Q954H, that were consi sporadic and not simultaneous with clinical detection. Secondly, there were mutations, such
as S371F, N501Y, and Q954H, that were consistently found in both sample types throughout
the sampling period. These mutations are as S371F, N501Y, and Q954H, that were consistently found in both sample types throughout
the sampling period. These mutations are high frequency mutations (above 50% prevalence
worldwide and in Portugal), making them easie the sampling period. These mutations are high frequency mutations (above 50% prevalence
worldwide and in Portugal), making them easier to detect consistently.
Lastly, a third set of mutations, e.g., L5F, A27S, and N185D, w

worldwide and in Portugal), making them easier to detect consistently.
473 Lastly, a third set of mutations, e.g., L5F, A27S, and N185D, were frec
474 samples throughout the sampling period but only sporadically in waste
4 Lastly, a third set of mutations, *e.g.*, L5F, A27S, and N185D, were frequently found in clinical
474 samples throughout the sampling period but only sporadically in wastewater samples. These
475 mutations are also of low samples throughout the sampling period but only sporadically in wastewater samples. These
475 mutations are also of low frequency but are almost exclusively associated with clinical
476 samples. During this analysis, we al mutations are also of low frequency but are almost exclusively associated with clinical
476 samples. During this analysis, we also noticed that many of these mutations occurred in the
477 BetaCoV_S1-NTD domain of the Spike samples. During this analysis, we also noticed that many of these mutations occurred in the
477 BetaCoV_S1-NTD domain of the Spike protein.
478 We then assessed the density of mutations in each category (exclusive to clini

BetaCoV_S1-NTD domain of the Spike protein.
478 We then assessed the density of mutations in
479 exclusive to wastewater samples, or found in l
480 structural regions of the Spike protein (Figure We then assessed the density of mutations in each category (exclusive to clinical samples,
exclusive to wastewater samples, or found in both sample types) within the functional and
structural regions of the Spike protein (exclusive to wastewater samples, or found in both sample types) within the functional and
480 structural regions of the Spike protein (Figure 3D), taking into account also the horizontal
481 coverage of each region (Figure structural regions of the Spike protein (Figure 3D), taking into account also the horizontal
481 coverage of each region (Figure 3E). We observed a coverage bias towards specific regions,
482 particularly the superimposed coverage of each region (Figure 3E). We observed a coverage bias towards specific regions,
particularly the superimposed Domain 2 – BetaCoV S1-CTD, and Region 7. Notably, these
regions are those where we most frequently de particularly the superimposed Domain 2 – BetaCoV S1-CTD, and Region 7. Notably, these

regions are those where we most frequently detect the same mutations in both sample types.

21 483 regions are those where we most frequently detect the same mutations in both sample types.
21

- 484 Thus, two factors may influence our ability to detect mutations in wastewater samples

485 through S gene sequencing: the coverage of the S gene and the mutation frequency.

486
- 485 through S gene sequencing: the coverage of the S gene and the mutation frequency.
486
386

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297774;](https://doi.org/10.1101/2023.10.30.23297774) this version posted October 31, 2023. The copyright holder for this preprint

488
489
490
492
493
493 489
490
491
493
494 Figure 3: Occurrence of specific missense substitutions. A. The pie chart shows the relative

490 proportions of substitutions found only in wastewater (WW) samples, only in Clinical samples and in

491 both. B. The top ba proportions of substitutions found only in wastewater (WW) samples, only in Clinical samples and in
491 both. B. The top bar plot shows how the relative proportion of missense substitutions found only in
492 WW samples, on both. B. The top bar plot shows how the relative proportion of missense substitutions found only in
492 WW samples, only in Clinical samples or in both varies per week. The bottom box plots show the
493 distribution of S g WW samples, only in Clinical samples or in both varies per week. The bottom box plots show the distribution of S gene horizontal coverage as in Figure 2C. C. For the set of substitutions that were found in both sample type distribution of S gene horizontal coverage as in Figure 2C. C. For the set of substitutions that were
494 found in both sample types (i.e., Clinical and WW), the occurrence per week in one of the samples,
495 both or none found in both sample types (i.e., Clinical and WW), the occurrence per week in one of the samples,
both or none is shown. D. Spike protein annotation with the Regions, Domains and Motifs analyzed in
panel E. E. For each Sp both or none is shown. D. Spike protein annotation with the Regions, Domains and Motifs analyzed in

496 panel E. E. For each Spike protein Region, Domain, Motif and Coiled coil, the average coverage and

497 the density o panel E. E. For each Spike protein Region, Domain, Motif and Coiled coil, the average coverage and

497 the density of mutated positions only found mutated in WW, Clinical, or in both samples, are shown.

498 Region_01, mu the density of mutated positions only found mutated in WW, Clinical, or in both samples, are shown.

498 Region_01, multiple occurrences of disordered region_02, putative superantigen; may bind T-

499 cell receptor alpha/ Region_01, multiple occurrences of disordered region. Region_02, putative superantigen; may bind T-

499 cell receptor alpha/TRAC. Region_03, receptor-binding domain (RBD). Region_04, integrin-binding

500 motif. Region_05 cell receptor alpha/TRAC. Region_03, receptor-binding domain (RBD). Region_04, integrin-binding

500 motif. Region_05, receptor-binding motif; binding to human ACE2. Region_06, immunodominant HLA

501 epitope recognized by motif. Region_05, receptor-binding motif; binding to human ACE2. Region_06, immunodominant HLA

501 epitope recognized by the CD8+; called NF9 peptide. Region_07, putative superantigen; may bind T-

502 cell receptor beta/ epitope recognized by the CD8+; called NF9 peptide. Region_07, putative superantigen; may bind T-

502 cell receptor beta/TRBC1. Region_08, fusion peptide 1. Region_09, fusion peptide 2. Region_10,

503 heptad repeat 1. Re cell receptor beta/TRBC1. Region_08, fusion peptide 1. Region_09, fusion peptide 2. Region_10,
503 heptad repeat 1. Region_11, heptad repeat 2. Domain_01, BetaCoV S1-NTD.
504 Domain_02, BetaCoV S1-CTD. Motif_01, binding to 503 heptad repeat 1. Region_11, heptad repeat 2. Domain_01, BetaCoV S1-NTD.
504 Domain_02, BetaCoV S1-CTD. Motif_01, binding to host endocytosis trafficking protein SNX27.
505 Motif_02, diacidic ER export motif (host COPII 504 Domain_02, BetaCoV S1-CTD. Motif_01, binding to host endocytosis trafficking protein SNX27.
505 Motif_02, diacidic ER export motif (host COPII). Motif_03, binding to host plasma membrane
506 Iocalizing/FERM domain prot 505 Motif_02, diacidic ER export motif (host COPII). Motif_03, binding to host plasma membrane
506 Iocalizing/FERM domain proteins. Motif_04, KxHxx, ER retrieval signal (COPI).
507 localizing/FERM domain proteins. Motif_04, KxHxx, ER retrieval signal (COPI).

Wastewater sequencing reveals low-frequency mutations missed by clinical
509 surveillance
510 We-then-directed-our-attention-to-missense-SNPs-exclusively-found-in-wastewater-samples.
511 Interestingly other studies have-al

509 **surveillance**
510 We then director
511 Interestingly,
512 reported in cl We then directed our attention to missense SNPs exclusively found in wastewater samples.

511 Interestingly, other studies have also identified mutations in wastewater that were not

512 Interesting in clinical samples col Interestingly, other studies have also identified mutations in wastewater that were not

state reported in clinical samples collected during the same period (Izquierdo-Lara et al., 2021,

513 2023; Smyth et al., 2022).

51

514 First, we investigated in worldwide clinical samples the presence of mutations identified
515 exclusively in wastewater samples from Portugal and found that all, except two, have been 513 2023; Smyth et al., 2022).
514 First, we investigated in
515 exclusively in wastewater
516 previously identified either 514 First, we investigated in worldwide clinical samples the presence of mutations identified
515 exclusively in wastewater samples from Portugal and found that all, except two, have been
516 previously identified, either exclusively in wastewater samples from Portugal and found that all, except two, have been

previously identified, either in Portugal before our sampling period, or in other countries. Two

517 mutations, G381R and Q607R, w previously identified, either in Portugal before our sampling period, or in other countries. Two
517 mutations, G381R and Q607R, were detected in our wastewater samples 11.5 and 9.7
518 months, respectively, before being r mutations, G381R and Q607R, were detected in our wastewater samples 11.5 and 9.7
518 months, respectively, before being reported in Portuguese clinical samples. This highlights
519 the power of WBS to detect low-frequency months, respectively, before being reported in Portuguese clinical samples. This highlights
519 the power of WBS to detect low-frequency mutations, which is due to its intrinsic ability to
520 sample a large population and 520 sample a large population and capture the underlying viral genetic diversity. Additionally, the
521 mutations D578E and T998K were never previously detected worldwide, emphasizing WBS's
522 ability to uncover novel mut sample a large population and capture the underlying viral genetic diversity. Additionally, the
521 mutations D578E and T998K were never previously detected worldwide, emphasizing WBS's
522 ability to uncover novel mutatio mutations D578E and T998K were never previously detected worldwide, emphasizing WBS's
522 ability to uncover novel mutations, which could potentially originate from unsampled infected
523 individuals, viral tropism to diff ability to uncover novel mutations, which could potentially originate from unsampled infected

individuals, viral tropism to different anatomical locations, such as the gastrointestinal tract,

prolonged COVID-19 infection individuals, viral tropism to different anatomical locations, such as the gastrointestinal tract,
524 prolonged COVID-19 infection which potentiates in-host evolution, or even an animal
525 reservoir (Gregory et al., 2022; prolonged COVID-19 infection which potentiates in-host evolution, or even an animal
525 reservoir (Gregory et al., 2022; Smyth et al., 2022).
526 We then investigated the distribution of wastewater missense SNPs not detect

reservoir (Gregory et al., 2022; Smyth et al., 2022).
526 We then investigated the distribution of wastewater missense SNPs not detected in our
527 clinical samples across different countries (Figure 4A). It became apparen We then investigated the distribution of wastewater missense SNPs not detected in our

state clinical samples across different countries (Figure 4A). It became apparent that some

mutations emerged in multiple countries, w clinical samples across different countries (Figure 4A). It became apparent that some
mutations emerged in multiple countries, while others were detected only in a few countries
(Figure 4A). The countries with higher numbe mutations emerged in multiple countries, while others were detected only in a few countries

529 (Figure 4A). The countries with higher numbers of sequenced clinical samples (Figure 4A,

530 bar chart in green) reported mo 529 (Figure 4A). The countries with higher numbers of sequenced clinical samples (Figure 4A,
530 bar chart in green) reported more mutations, and the mutations found at higher frequencies
531 (Figure 4A, bar chart in blue) bar chart in green) reported more mutations, and the mutations found at higher frequencies
531 (Figure 4A, bar chart in blue) were identified across more countries. These results highlight
532 the influence of mutation fre 531 (Figure 4A, bar chart in blue) were identified across more countries. These results highlight
532 the influence of mutation frequency on the ability to capture the full extent of viral genetic
533 diversity and emphasi the influence of mutation frequency on the ability to capture the full extent of viral genetic
533 diversity and emphasize the importance of sequencing more samples to identify low-
534 frequency mutations. Note that the m diversity and emphasize the importance of sequencing more samples to identify low-
534 frequency mutations. Note that the mutations detected solely through wastewater S gene
535 sequencing are present in very low frequenci frequency mutations. Note that the mutations detected solely through wastewater S gene
535 sequencing are present in very low frequencies in clinical samples worldwide (ranging from
24 535 sequencing are present in very low frequencies in clinical samples worldwide (ranging from
24

 $2.09x10^{-7}$ to 8.55x10⁻²; Figure 4B), whereas they exhibit a diverse frequency range in our

2.09x10^{-/} to 8.55x10⁻²; Figure 4B), whereas they exhibit a diverse frequency range in our
537 wastewater sample dataset (Figure 4C).
538 These findings highlight the need for an extensive sequencing effort to identify wastewater sample dataset (Figure 4C).
538 These findings highlight the need for
539 mutations, likely explaining why they
540 Portugal It also underscores the impor 538 These findings highlight the need for an extensive sequencing effort to identify rare
539 mutations, likely explaining why they have been overlooked in clinical surveillance in
540 Portugal. It also underscores the imp mutations, likely explaining why they have been overlooked in clinical surveillance in
540 Portugal. It also underscores the importance of comprehensive clinical sampling to detect
541 such infrequent mutations or alternat 540 Portugal. It also underscores the importance of comprehensive clinical sampling to detect
541 such infrequent mutations or alternatively, the adoption of WBS, which can efficiently track
542 low-frequency mutations by 541 such infrequent mutations or alternatively, the adoption of WBS, which can efficiently track
542 low-frequency mutations by sampling a larger population in one go.
543 542 low-frequency mutations by sampling a larger population in one go.
543

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297774;](https://doi.org/10.1101/2023.10.30.23297774) this version posted October 31, 2023. The copyright holder for this preprint

545
546
548
549
555
555 546
547
548
550
551 Figure 4: Amino acid substitution mutations in the S gene only identified in WW samples that

were not identified in Portugal's clinical samples. A. A heat map of occurrence (presence in blue,

absence in red) of each muta were not identified in Portugal's clinical samples. A. A heat map of occurrence (presence in blue,
548 absence in red) of each mutation detected in WW samples from Portugal, absent from the clinical
559 surveillance compon absence in red) of each mutation detected in WW samples from Portugal, absent from the clinical
549 surveillance component in Portugal, but present in clinical samples from countries other than Portugal.
550 Rows correspon surveillance component in Portugal, but present in clinical samples from countries other than Portugal.
550 Rows correspond to the mutations and columns to countries. Mutations and countries are sorted by
551 the mean valu Rows correspond to the mutations and columns to countries. Mutations and countries are sorted by
551 the mean value of rows and columns, which is reflected in the clustering dendrograms. The green bar
552 plot on the botto the mean value of rows and columns, which is reflected in the clustering dendrograms. The green bar

plot on the bottom of the heatmap shows the number of clinical SARS-CoV-2 sequences available for

each country, highligh plot on the bottom of the heatmap shows the number of clinical SARS-CoV-2 sequences available for
553 each country, highlighting the different sequencing efforts of each country. Palestine and Saint
554 Eustatius and Saba each country, highlighting the different sequencing efforts of each country. Palestine and Saint
554 Eustatius and Saba are not considered as independent territories in GISAID, contrary to OutbreakInfo,
555 and their seque Eustatius and Saba are not considered as independent territories in GISAID, contrary to OutbreakInfo,
555 and their sequencing efforts are included in Israel and The Netherlands, respectively. The blue bar
556 plot of the and their sequencing efforts are included in Israel and The Netherlands, respectively. The blue bar

556 plot of the right represents the number of sequences containing the mutation in the set of all available

557 clinica 556 plot of the right represents the number of sequences containing the mutation in the set of all available
557 clinical sequences, highlighting that this set of mutations occurs rarely. B. Violin plot showing the
558 dis clinical sequences, highlighting that this set of mutations occurs rarely. B. Violin plot showing the
558 distribution of the frequencies of these mutations in the represented countries, once again highlighting
559 that th 558 distribution of the frequencies of these mutations in the represented countries, once again highlighting
559 that these mutations occur in very low frequencies. C. Box plots representing the frequency of these
560 muta 559 that these mutations occur in very low frequencies. C. Box plots representing the frequency of these
560 mutations in the WWTPs analyzed in this study.
562 The S gene sequencing-based lineage assignment inadequately ca 144

1445

1544

1545

1546 **linear of identified in I**

1555

1658 absence in red) of each

1555

1679 Rows correspond to the

1555

1655

1679 Brazil Italy Spain Canada Saba are

1555

1555 and their sequencing ef

1555

-
-

560 mutations in the WWTPs analyzed in this study.
561
562 **The S gene sequencing-based lineage** 562
563
564 562 563 **The S gene sequencing-based lineage assignment inadequately captures Omicron**

WBS gained traction during the COVID-19 pandemic, leading to the development of multiple
tools for SARS-CoV-2 lineage assignment from challenging mixed sample sequencing data
(Amman et al., 2022; Karthikeyan et al., 2022; tools for SARS-CoV-2 lineage assignment from challenging mixed sample sequencing data

(Amman et al., 2022; Karthikeyan et al., 2022; Sapoval et al., 2023). The regular emergence

of new lineages with increasing shared mut (Amman et al., 2022; Karthikeyan et al., 2022; Sapoval et al., 2023). The regular emergence
568 of new lineages with increasing shared mutations challenges accurate lineage identification
569 (Fontenele et al., 2021; Izqui 568 of new lineages with increasing shared mutations challenges accurate lineage identification
569 (Fontenele et al., 2021; Izquierdo-Lara et al., 2021; Swift et al., 2022). With over 300
570 Omicron sub-lineages, high-qu 569 (Fontenele et al., 2021; Izquierdo-Lara et al., 2021; Swift et al., 2022). With over 300
570 Omicron sub-lineages, high-quality sequencing data becomes increasingly crucial for lineage
571 assignment.
572 Given our sub Omicron sub-lineages, high-quality sequencing data becomes increasingly crucial for lineage
571 assignment.
572 Given our sub-optimal sequencing data of the S gene from mixed samples containing
573 multiple SARS-CoV-2 line

571 assignment.
572 Given our s
573 multiple SAF
574 required a.rc 572 Given our sub-optimal sequencing data of the S gene from mixed samples containing
573 multiple SARS-CoV-2 lineages, and the low horizontal coverage of a few samples, we
574 required a robust bioinformatics tool for lin 574 mequired a robust bioinformatics tool for lineage assignment. Freyja pipeline demonstrated
575 multiple Saperior performance compared to other deconvolution methods (Baaijens et al., 2021;
576 Matharina et al., 2022; V required a robust bioinformatics tool for lineage assignment. Freyja pipeline demonstrated

superior performance compared to other deconvolution methods (Baaijens et al., 2021;

Katharina et al., 2022; Valieris et al., 202 superior performance compared to other deconvolution methods (Baaijens et al., 2021;
576 Katharina et al., 2022; Valieris et al., 2022) in terms of accuracy, false-positive rate, and
577 computational efficiency, making it Katharina et al., 2022; Valieris et al., 2022) in terms of accuracy, false-positive rate, and
577 computational efficiency, making it the selected method for this study.
578 We attempted lineage assignment in all 332 seque

computational efficiency, making it the selected method for this study.
578 We attempted lineage assignment in all 332 sequenced samples
579 summarized in Figure 1C. The resolution achieved by Freyja was r
580 make assignm 578 We attempted lineage assignment in all 332 sequenced samples, and the results are
579 summarized in Figure 1C. The resolution achieved by Freyja was not always sufficient to
580 make assignments at the level obtained w summarized in Figure 1C. The resolution achieved by Freyja was not always sufficient to
580 make assignments at the level obtained with the RT-PCR genotyping assays, specifically for
581 the major Omicron lineages, leading make assignments at the level obtained with the RT-PCR genotyping assays, specifically for
581 the major Omicron lineages, leading to a high frequency of the 'Others' category. The
582 limitations arise from the low and un the major Omicron lineages, leading to a high frequency of the 'Others' category. The
582 limitations arise from the low and uneven S-gene horizontal coverage in our samples, with
583 average values below 25% in several sa Imitations arise from the low and uneven S-gene horizontal coverage in our samples, with
state average values below 25% in several samples, along with the low number of samples
analysed per week (Figure 1D), which collecti 583 average values below 25% in several samples, along with the low number of samples
584 analysed per week (Figure 1D), which collectively hinder the assignment success and the
585 effective ability to capture the progres analysed per week (Figure 1D), which collectively hinder the assignment success and the

effective ability to capture the progression of sub-lineages and discriminate within.

Nonetheless, the major Omicron sub-lineages ci

effective ability to capture the progression of sub-lineages and discriminate within.
586 Nonetheless, the major Omicron sub-lineages circulating in our sampling period (*i.*
587 BA.2.X, BA.4.X, BA5.X, and XBB.X) have also 587 BA.2.X, BA.4.X, BA5.X, and XBB.X) have also been detected. BA.1.X was consistently
588 present throughout the sampling period (*Figure 1C*), despite representing a residual
589 frequency of SARS-CoV-2 infections accord BA.2.X, BA.4.X, BA5.X, and XBB.X) have also been detected. BA.1.X was consistently

present throughout the sampling period (Figure 1C), despite representing a residual

frequency of SARS-CoV-2 infections according to clini present throughout the sampling period (Figure 1C), despite representing a residual
589 frequency of SARS-CoV-2 infections according to clinical and genotyping assays (Figure 1A
590 and 1B). BA.2.X was detected throughout frequency of SARS-CoV-2 infections according to clinical and genotyping assays (Figure 1A
590 and 1B). BA.2.X was detected throughout the sampling period, gradually decreasing in
591 frequency, particularly evident after t 590 and 1B). BA.2.X was detected throughout the sampling period, gradually decreasing in
591 frequency, particularly evident after the rise of XBB.X infections in week 5 of 2023. BA.4.X
592 was always detected, but with hi 591 frequency, particularly evident after the rise of XBB.X infections in week 5 of 2023. BA.4.X
592 was always detected, but with higher proportions until week 46 of 2022 (Figure 1C), when it
27 592 was always detected, but with higher proportions until week 46 of 2022 (Figure 1C), when it

also decreased detection by both genotyping assays and clinical surveillance (Figure 1A and
594 1B). BA.5.X appeared throughout the sampling period (Figure 1C), aligning with clinical data
595 as the dominant sub-lineage (1B). BA.5.X appeared throughout the sampling period (Figure 1C), aligning with clinical data
ss as the dominant sub-lineage (Figure 1A). Its frequency gradually reduced with the rise of
S96 XBB.X sub-lineage. XBB.X was fir 595 as the dominant sub-lineage (Figure 1A). Its frequency gradually reduced with the rise of
596 XBB.X sub-lineage. XBB.X was first identified by S gene sequencing in week 42 of 2022
597 (Figure 1C), coinciding with its f XBB.X sub-lineage. XBB.X was first identified by S gene sequencing in week 42 of 2022
597 (Figure 1C), coinciding with its first detection in clinical data (Figure 1A).
598 The results obtained from S gene sequencing-depen

597 (Figure 1C), coinciding with its first detection in clinical data (Figure 1A).
598 The results obtained from S gene sequencing-dependent lineage ass
599 genotyping assays and clinical surveillance, but the progression The results obtained from S gene sequencing-dependent lineage assignment agree with
genotyping assays and clinical surveillance, but the progression of Omicron sub-lineages is
not well captured by this methodology, likely 599 genotyping assays and clinical surveillance, but the progression of Omicron sub-lineages is
600 not well captured by this methodology, likely due to coverage constraints in complex mixed-
601 samples like wastewater.
6 600 not well captured by this methodology, likely due to coverage constraints in complex mixed-
601 samples like wastewater.
602 **DISCUSSION** 601 samples like wastewater.
602
603 DISCUSSION
604 Genomic surveillance of

602
603
604
605 603 **DISCUSSION**
604 Genomic surv
605 providing vital
606 effective contra 604 Genomic surveillance of SARS-CoV-2 played a crucial role in the COVID-19 pandemic,
605 providing vital information for understanding virus transmission and evolution, and guiding
606 effective control measures. However 605 providing vital information for understanding virus transmission and evolution, and guiding
606 effective control measures. However, with the success of vaccination campaigns leading to a
607 decline in infections and effective control measures. However, with the success of vaccination campaigns leading to a
decline in infections and their severity, the focus on genomic surveillance has gradually
decreased worldwide since December 2022, decreased worldwide since December 2022, and in Portugal since May 2022, when the
609 country testing strategy changed. While understandable, given the current impact of the
610 pandemic, this reduction leaves us unaware o decreased worldwide since December 2022, and in Portugal since May 2022, when the
609 country testing strategy changed. While understandable, given the current impact of the
610 pandemic, this reduction leaves us unaware o 609 country testing strategy changed. While understandable, given the current impact of the
610 pandemic, this reduction leaves us unaware of the ongoing infection dynamics and emerging
611 variants. As a result, more reso pandemic, this reduction leaves us unaware of the ongoing infection dynamics and emerging
611 variants. As a result, more resource-efficient methods like WBS have been explored for
612 population-wide genomic surveillance. variants. As a result, more resource-efficient methods like WBS have been explored for
612 population-wide genomic surveillance. To validate and optimize this new approach, it must
613 be rigorously compared with current c 612 population-wide genomic surveillance. To validate and optimize this new approach, it must
613 be rigorously compared with current clinical surveillance methods, addressing challenges,
614 and implementing necessary imp be rigorously compared with current clinical surveillance methods, addressing challenges,
614 and implementing necessary improvements.
615 Here, we conducted one year of wastewater-based surveillance on the Portuguese
616

and implementing necessary improvements.
615 Here, we conducted one year of wastewater-based surveillance on the Portuguese
616 population, spanning from May 2022, when clinical surveillance sequencing efforts began to
617 Fitch Here, we conducted one year of wastewater-based surveillance on the Portuguese
616 population, spanning from May 2022, when clinical surveillance sequencing efforts began to
617 decline, until April 2023. The dynamic population, spanning from May 2022, when clinical surveillance sequencing efforts began to
617 decline, until April 2023. The dynamics of SARS-CoV-2 were monitored using a combined
618 approach of RT-PCR genotyping assays decline, until April 2023. The dynamics of SARS-CoV-2 were monitored using a combined
618 approach of RT-PCR genotyping assays and targeted S gene sequencing.
619 Screening signature Omicron sub-lineage mutations via RT-PC

618 approach of RT-PCR genotyping assays and targeted S gene sequencing.
619 Screening signature Omicron sub-lineage mutations via RT-PCR offers a
620 method, providing community-level insights and adaptability to emerging 619 Screening signature Omicron sub-lineage mutations via RT-PCR offers a fast and efficient
620 method, providing community-level insights and adaptability to emerging mutations, making it
28 620 method, providing community-level insights and adaptability to emerging mutations, making it

a valuable addition to epidemiological surveillance. Moreover, it reduces costs compared to
622 high-throughput sequencing, enabling broader implementation. However, this approach is
623 limited to the identification of kn high-throughput sequencing, enabling broader implementation. However, this approach is

filmited to the identification of known sub-lineages with well-known diagnostic mutations and

its discriminatory power diminishes wit limited to the identification of known sub-lineages with well-known diagnostic mutations and
624 its discriminatory power diminishes with extensive Omicron VOC diversification. Additionally,
625 targeted RT-PCR genotyping its discriminatory power diminishes with extensive Omicron VOC diversification. Additionally,

fargeted RT-PCR genotyping assays cannot detect new unknown lineages, low frequency

mutations, or novel mutations. They also p targeted RT-PCR genotyping assays cannot detect new unknown lineages, low frequency
mutations, or novel mutations. They also provide limited information about which variants are
responsible for the overall increase or decr mutations, or novel mutations. They also provide limited information about which variants are
627 responsible for the overall increase or decrease of SARS-CoV-2 viral load in sewage due to
628 their inability to determine responsible for the overall increase or decrease of SARS-CoV-2 viral load in sewage due to
628 their inability to determine lineage frequencies in these very complex samples. Thus,
629 wastewater-based surveillance via RTtheir inability to determine lineage frequencies in these very complex samples. Thus,
wastewater-based surveillance via RT-PCR genotyping alone cannot fully match the
comprehensive information obtained from clinical genomi wastewater-based surveillance via RT-PCR genotyping alone cannot fully match the
630 comprehensive information obtained from clinical genomic surveillance.
631 High-throughput sequencing methods offer significant advantage

comprehensive information obtained from clinical genomic surveillance.
631 High-throughput sequencing methods offer significant advantages, pro
632 Iess biased overview of viral genetic diversity and enabling detection
633 High-throughput sequencing methods offer significant advantages, providing a broader and
632 less biased overview of viral genetic diversity and enabling detection of novel lineages,
633 tracking low-frequency mutations, a less biased overview of viral genetic diversity and enabling detection of novel lineages,
tracking low-frequency mutations, and identification of mutational hotspots. However, our
data highlights the challenges inherent to tracking low-frequency mutations, and identification of mutational hotspots. However, our
634 data highlights the challenges inherent to wastewater samples, such as biological
635 complexity, enzymatic inhibitors, viral RN data highlights the challenges inherent to wastewater samples, such as biological
635 complexity, enzymatic inhibitors, viral RNA concentration and integrity, which are critical
636 factors to obtaining high quality sample complexity, enzymatic inhibitors, viral RNA concentration and integrity, which are critical
factors to obtaining high quality samples required for successful sequencing and full
computational analyses (Izquierdo-Lara et al factors to obtaining high quality samples required for successful sequencing and full

computational analyses (Izquierdo-Lara et al., 2021). Particularly evident is the impact

introduced by samples in which S gene coverag computational analyses (Izquierdo-Lara et al., 2021). Particularly evident is the impact
introduced by samples in which S gene coverage is low, leading to an underestimation of
mutational diversity and hindering lineage at introduced by samples in which S gene coverage is low, leading to an underestimation of

mutational diversity and hindering lineage attribution, preventing the full reproduction of the

Comicron sub-lineage succession patt mutational diversity and hindering lineage attribution, preventing the full reproduction of the
640 Omicron sub-lineage succession patterns observed in clinical surveillance. As other authors
641 already pointed out, in ou 640 Omicron sub-lineage succession patterns observed in clinical surveillance. As other authors
641 already pointed out, in our work, no correlation was found between S gene coverage and
642 RNA concentration or viral load 641 already pointed out, in our work, no correlation was found between S gene coverage and
642 RNA concentration or viral load (Izquierdo-Lara et al., 2021; Pérez-Cataluña et al., 2022),
643 therefore other parameters such RNA concentration or viral load (Izquierdo-Lara et al., 2021; Pérez-Cataluña et al., 2022),
therefore other parameters such as wastewater storage, pre-process and concentration
before nucleic acid extraction, or biases int therefore other parameters such as wastewater storage, pre-process and concentration
644 before nucleic acid extraction, or biases introduced by library construction and amplicon
645 sequencing strategies, need to be analy sequencing strategies, need to be analysed to infer their impact on RNA recovery and,
646 consequently, on sequencing performance (Perez-Zabaleta et al., 2023; Tamáš et al., 2022).
647 Genomics is a rapidly growing field t sequencing strategies, need to be analysed to infer their impact on RNA recovery and,

consequently, on sequencing performance (Perez-Zabaleta et al., 2023; Tamáš et al., 2022).

Genomics is a rapidly growing field that ca 646 consequently, on sequencing performance (Perez-Zabaleta et al., 2023; Tamáš et al., 2022).
647 Genomics is a rapidly growing field that can yield useful information for public health
648 surveillance, particularly duri 647 Genomics is a rapidly growing field that can yield useful information for public health
648 surveillance, particularly during ongoing disease outbreaks. Many factors currently affect
29 648 surveillance, particularly during ongoing disease outbreaks. Many factors currently affect

649 sequencing quality (*e.g.* coverage), influencing the full applicability of genomic data. Critical
650 in the clinical and wastewater contexts is that not all available samples have the same
651 potential to result in 650 in the clinical and wastewater contexts is that not all available samples have the same
651 potential to result in high quality sequencing outcomes, such as genome depth and
652 coverage. Since horizontal coverage of t potential to result in high quality sequencing outcomes, such as genome depth and
652 coverage. Since horizontal coverage of the S gene may hinder the comprehensive detection
653 of the wide spectrum of mutations circulati 652 coverage. Since horizontal coverage of the S gene may hinder the comprehensive detection
653 of the wide spectrum of mutations circulating on a given population at the sewershed level, it
654 is crucial to invest effor 653 of the wide spectrum of mutations circulating on a given population at the sewershed level, it
654 is crucial to invest efforts alongside the entire genomics workflow, from sample collection and
655 sample processing t is crucial to invest efforts alongside the entire genomics workflow, from sample collection and
655 sample processing to library construction, sequencing technology and sequence data
656 analyses, to obtain more accurate a sample processing to library construction, sequencing technology and sequence data
656 analyses, to obtain more accurate and representative outputs. Predictive models of resulting
657 sequencing depth and coverage based on analyses, to obtain more accurate and representative outputs. Predictive models of resulting
657 sequencing depth and coverage based on known variables associated with collected
658 samples are thus in great demand.
659 Th sequencing depth and coverage based on known variables associated with collected
658 samples are thus in great demand.
659 The genotyping assays allowed the identification of mutation alleles found in one or more
660 Omicr

658 samples are thus in great demand.
659 The genotyping assays allowed th
660 Omicron sub-lineages, frequently
661 Surveillance data This time lanse The genotyping assays allowed the identification of mutation alleles found in one or more
660 Omicron sub-lineages, frequently for longer periods compared to the clinical genomic
661 surveillance data. This time lapse coul 660 Omicron sub-lineages, frequently for longer periods compared to the clinical genomic
661 surveillance data. This time lapse could be attributed to the larger population sampled in
662 WBS, where one weekly wastewater s surveillance data. This time lapse could be attributed to the larger population sampled in
662 WBS, where one weekly wastewater sample represents up to 920000 people, whereas in
663 clinical surveillance, an average of 134 WBS, where one weekly wastewater sample represents up to 920000 people, whereas in

clinical surveillance, an average of 134 persons were sampled per week. It can also reflect

the less biased sampling approach in WBS, whi clinical surveillance, an average of 134 persons were sampled per week. It can also reflect
the less biased sampling approach in WBS, which includes both symptomatic and
asymptomatic individuals, and the fact that in clini the less biased sampling approach in WBS, which includes both symptomatic and
665 asymptomatic individuals, and the fact that in clinical surveillance, the presence of the virus
666 is tested once (usually at the onset of asymptomatic individuals, and the fact that in clinical surveillance, the presence of the virus
666 is tested once (usually at the onset of infection), while in WBS it is detected for the full
667 infection period. During is tested once (usually at the onset of infection), while in WBS it is detected for the full
infection period. During that period, the ongoing excretion of viral RNA in faeces can persist
approximately for an average durat infection period. During that period, the ongoing excretion of viral RNA in faeces can persist
668 approximately for an average duration of 14-21 days (Lescure et al., 2020; Pan et al., 2020),
669 with SARS-CoV-2 shedding approximately for an average duration of 14-21 days (Lescure et al., 2020; Pan et al., 2020),
with SARS-CoV-2 shedding having been reported for up to 55 days in patients with
complications or admitted to intensive care uni with SARS-CoV-2 shedding having been reported for up to 55 days in patients with
670 complications or admitted to intensive care units (Lavania et al., 2022).
671 Another relevant aspect of our analysis concerns low-freque

complications or admitted to intensive care units (Lavania et al., 2022).
671 Another relevant aspect of our analysis concerns low-frequency mutations
672 were first detected in wastewater samples and much later in clinic
 Another relevant aspect of our analysis concerns low-frequency mutations, including two that
672 were first detected in wastewater samples and much later in clinical samples, and two
673 mutations never previously reported were first detected in wastewater samples and much later in clinical samples, and two
673 mutations never previously reported worldwide. This is in line with other wastewater
674 sequencing surveillance initiatives, where mutations never previously reported worldwide. This is in line with other wastewater
674 sequencing surveillance initiatives, where mutations in Spike were identified months before
675 being reported in clinical samples (I 674 sequencing surveillance initiatives, where mutations in Spike were identified months before
675 being reported in clinical samples (Izquierdo-Lara et al., 2023; La Rosa et al., 2023; Pérez-
676 Cataluña et al., 2022), 675 being reported in clinical samples (Izquierdo-Lara et al., 2023; La Rosa et al., 2023; Pérez-
676 Cataluña et al., 2022), highlighting the potential of wastewater surveillance as an early
30 676 Cataluña et al., 2022), highlighting the potential of wastewater surveillance as an early

warning system. For example, and considering the most recent variant of interest EG.5, a
678 descendent of XBB.1.X (risk evaluation from 9 August 2023, by WHO), this lineage was
679 identified in very low-frequency in our descendent of XBB.1.X (risk evaluation from 9 August 2023, by WHO), this lineage was
identified in very low-frequency in our wastewater samples from week 16 of 2023, however it
was reported on clinical data only from week identified in very low-frequency in our wastewater samples from week 16 of 2023, however it
was reported on clinical data only from week 18 onward, re-enforcing the capability of WBS
to anticipate trends and upsurges in a was reported on clinical data only from week 18 onward, re-enforcing the capability of WBS
681 to anticipate trends and upsurges in a given region.
682 Early detection of low-frequency mutations is crucial to monitor the e

681 to anticipate trends and upsurges in a given region.
682 Early detection of low-frequency mutations is crucia
683 2, as they serve as the basis for natural selection
684 that may be more transmissible or cause more sev Early detection of low-frequency mutations is crucial to monitor the evolution of SARS-CoV-
683 2, as they serve as the basis for natural selection and can give rise to new VOCs/lineages
684 that may be more transmissible 2, as they serve as the basis for natural selection and can give rise to new VOCs/lineages
684 that may be more transmissible or cause more severe infections. We observed that several
685 low-frequency mutations were detec that may be more transmissible or cause more severe infections. We observed that several
Iow-frequency mutations were detected in clinical samples but not in wastewater samples,
Iikely due to their low frequency, making th Iow-frequency mutations were detected in clinical samples but not in wastewater samples,

686 likely due to their low frequency, making their detection more random in either sample type.

687 On the contrary, we also found Iikely due to their low frequency, making their detection more random in either sample type.
687 On the contrary, we also found several mutations in wastewater samples that were not
688 previously seen in Portugal through 687 On the contrary, we also found several mutations in wastewater samples that were not
688 previously seen in Portugal through clinical surveillance. Similar findings were also made by
689 Pérez-Cataluna and collaborator 688 previously seen in Portugal through clinical surveillance. Similar findings were also made by
689 Pérez-Cataluna and collaborators in Spain, and La Rosa and collaborators in Italy, with the
690 report of exclusive wast Férez-Cataluna and collaborators in Spain, and La Rosa and collaborators in Italy, with the
690 Feport of exclusive wastewater mutations or mutations not reported as dominant in clinical
691 Femples (La Rosa et al., 2023; report of exclusive wastewater mutations or mutations not reported as dominant in clinical
691 samples (La Rosa et al., 2023; Pérez-Cataluña et al., 2022). The report of novel amino acid
692 substitutions at Spike gene wer samples (La Rosa et al., 2023; Pérez-Cataluña et al., 2022). The report of novel amino acid
substitutions at Spike gene were also reported in other publications (Crits-Christoph et al.,
2021; Pérez-Cataluña et al., 2021; S substitutions at Spike gene were also reported in other publications (Crits-Christoph et al.,

693 2021; Pérez-Cataluña et al., 2021; Smyth et al., 2022).

694 The low-frequency and novel mutations may originate from unsam

2021; Pérez-Cataluña et al., 2021; Smyth et al., 2022).
694 The low-frequency and novel mutations may originate
695 tot unlikely given that our sampling period correspon
696 surveillance decreased in Portugal. The low-frequency and novel mutations may originate from unsampled individuals, which is

for the unlikely given that our sampling period corresponds to the time point in which clinical

surveillance decreased in Portugal. not unlikely given that our sampling period corresponds to the time point in which clinical
696 surveillance decreased in Portugal. They can also originate from asymptomatic cases,
697 viruses replicating in different body surveillance decreased in Portugal. They can also originate from asymptomatic cases,
697 viruses replicating in different body sites (e.g., respiratory vs. gastrointestinal tracts),
698 prolonged infections leading to in-h viruses replicating in different body sites (*e.g.*, respiratory *vs.* gastrointestinal tracts),
for prolonged infections leading to in-host evolution, or even from animal reservoirs whose
excretions also end up in the sam prolonged infections leading to in-host evolution, or even from animal reservoirs whose
excretions also end up in the same wastewater treatment plants (Gregory et al., 2022; Smyth
et al., 2022).
Although not able to comple excretions also end up in the same wastewater treatment plants (Gregory et al., 2022; Smyth

t al., 2022).

Although not able to completely replace clinical surveillance, allelic discrimination assays and

S gene sequencin

100 et al., 2022).
101 Although not
102 S gene seque
103 envision an Although not able to completely replace clinical surveillance, allelic discrimination assays and

702 S gene sequencing can complement each other to overcome their respective limitations. We

703 envision an implementation 702 S gene sequencing can complement each other to overcome their respective limitations. We

703 envision an implementation scheme in which the RT-PCR genotyping assays, selected

704 based on the data being collected wee 203 envision an implementation scheme in which the RT-PCR genotyping assays, selected

704 based on the data being collected weekly and by the sequencing results, allow fast testing of

31 704 based on the data being collected weekly and by the sequencing results, allow fast testing of

705 a large number of samples, covering a very large set of the population. Additionally,
706 successful implementation of S gene targeted sequencing in parallel will allow regular
707 monitoring of virus evolution and det 706 successful implementation of S gene targeted sequencing in parallel will allow regular
707 monitoring of virus evolution and detection, and tracking low-frequency mutations.
708 **CONCLUSION** 707 monitoring of virus evolution and detection, and tracking low-frequency mutations.

708
709
710
711 709 **CONCLUSION**
710 In summary, the
711 S gene sequen
712 lineages within 110 In summary, the combination of wastewater genomic surveillance using RT-PCR assays and

11 S gene sequencing provided useful insights into the diversity of circulating Omicron sub-

12 lineages within the sampled popul 711 S gene sequencing provided useful insights into the diversity of circulating Omicron sub-
712 lineages within the sampled population throughout 12 months. Although each method has its
713 own limitations in terms of li Ineages within the sampled population throughout 12 months. Although each method has its
713 own limitations in terms of lineage discrimination, when used together, they offer a reliable
714 snapshot of the local epidemiol own limitations in terms of lineage discrimination, when used together, they offer a reliable
714 snapshot of the local epidemiological situation. Additionally, this combined approach enables
715 fast lineage attribution a 9714 snapshot of the local epidemiological situation. Additionally, this combined approach enables

715 fast lineage attribution alongside the identification of low-frequency and novel mutations,

716 which would typically Fast lineage attribution alongside the identification of low-frequency and novel mutations,

716 which would typically require extensive clinical sampling and sequencing efforts. Further,

717 they support the prolonged de which would typically require extensive clinical sampling and sequencing efforts. Further,

717 they support the prolonged detection of lineages considered by clinical surveillance to be

718 already out of circulation. Th they support the prolonged detection of lineages considered by clinical surveillance to be

218 already out of circulation. The results generated in this work evidence the value of

219 environmental surveillance to captur 218 already out of circulation. The results generated in this work evidence the value of

219 environmental surveillance to capture public health trends and underscore the effectiveness

220 of WBS as a tracking system for environmental surveillance to capture public health trends and underscore the effectiveness
720 of WBS as a tracking system for virus variants. Moreover, WBS offers the opportunity to
721 transform the cost per clinical sa of WBS as a tracking system for virus variants. Moreover, WBS offers the opportunity to

1721 transform the cost per clinical sample into the cost per sewershed.

1722 In conclusion, our findings emphasize that knowledge o

transform the cost per clinical sample into the cost per sewershed.

722 In conclusion, our findings emphasize that knowledge of the genetical

723 at the population level can be extended far beyond via the com

724 aenomi In conclusion, our findings emphasize that knowledge of the genetic diversity of SARS-CoV-2

223 at the population level can be extended far beyond via the combination of routine clinical

224 genomic surveillance with was 123 at the population level can be extended far beyond via the combination of routine clinical
124 genomic surveillance with wastewater sequencing and genotyping.
125 ACKNOWLEDGMENTS 99 724 genomic surveillance with wastewater sequencing and genotyping.
125 **ACKNOWLEDGMENTS**
127 We acknowledge the coordination efforts of AdP VALOR from the very first moment,

726
727
728 726 **ACKNOWLEDGMENTS**
727 We acknowledge the or
728 particularly of Ana Katila
729 the Portuguese Environg We acknowledge the coordination efforts of AdP VALOR from the very first moment,

particularly of Ana Katila Ribeiro, Marta Carvalho and Nuno Brôco, and the engagement of

the Portuguese Environment Agency [APA] and the Na particularly of Ana Katila Ribeiro, Marta Carvalho and Nuno Brôco, and the engagement of
the Portuguese Environment Agency [APA] and the National Health Authority [DGS] as well,
in setting up a national surveillance system

the Portuguese Environment Agency [APA] and the National Health Authority [DGS] as well,
in setting up a national surveillance system. Thanks are due to Anabela Rebelo [APA].
We acknowledge the close collaboration of water 730 in setting up a national surveillance system. Thanks are due to Anabela Rebelo [APA].
731 We acknowledge the close collaboration of water utilities [AGERE, Águas do Algarve,
732 do Centro Litoral, Águas do Norte, Águas 731 We acknowledge the close collaboration of water utilities [AGERE, Aguas do Algarve, Aguas
732 do Centro Litoral, Águas do Norte, Águas do Tejo Atlântico, Águas e Energia do Porto,
32 732 do Centro Litoral, Águas do Norte, Águas do Tejo Atlântico, Águas e Energia do Porto,

733 SIMDOURO, SMAS Almada] along this project and thank all their employees who
734 contributed to wastewater sampling.
735 The institutional support of *Ministério do Ambiente e Ação Climática* and the European
736 Commis

%734 contributed to wastewater sampling.
735 The institutional support of *Ministé*
736 Commission's *DG Joint Research*
737 cratefully acknowledged 735 The institutional support of *Ministério do Ambiente e Ação Climática* and the European
736 Commission's *DG Joint Research Centre*, Directorate D – Sustainable Resources is
737 gratefully acknowledged. 736 Commission's *DG Joint Research Centre*, Directorate D – Sustainable Resources is
737 gratefully acknowledged.
738 **FUNDING** 737 gratefully acknowledged.
738
739 **FUNDING**
740 This work was supported.

739
740
741 739 **FUNDING**
740 This work
741 [Support to
742 digital infra This work was supported by the European Union through the Emergency Support Instrument

1741 [Support to the Member States to establish national systems, local collection points, and

1742 digital infrastructure for monito 741 [*Support to the Member States to establish national systems, local collection points, and
742 digital infrastructure for monitoring Covid19 and its variants in wastewater – Portugal; Grant
743 Agreement No. 060701/202 digital infrastructure for monitoring Covid19 and its variants in wastewater – Portugal*; Grant
743 Agreement No. 060701/2021/864489/SUB/ENV.C2], Fundo Ambiental (MAAC), and
744 Fundação para a Ciência e a Tecnologia, IP 743 Agreement No. 060701/2021/864489/SUB/ENV.C2], Fundo Ambiental (MAAC), and
744 Fundação para a Ciência e a Tecnologia, IP [institutional support to cE3c
745 (UIDB/00329/2020);BioISI(UIDB/04046/2020);andCHANGE(LA/P/0121/ 744 Fundação para a Ciência e a Tecnologia, IP [institutional support to cE3c (UIDB/00329/2020); BioISI (UIDB/04046/2020); and CHANGE (LA/P/0121/2020)].
746
CONFLICTS OF INTEREST
748 The authors declare no conflict of interest. The funders had no role in the design of the study;

747
748
749 747 **CONFLICTS OF INTEREST**
748 The authors declare no confli
749 in the collection, analyses, or
750 decision to publish the results The authors declare no conflict of interest. The funders had no role in the design of the study;
in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the
decision to publish the r The visit of data; in the writing of the manuscript, or in the decision to publish the results.

750 decision to publish the results.

751 **DATA AND MATERIALS AVAILARILITY**

750 decision to publish the results.
751 **DATA AND MATERIALS AVA**
753 Materials generated in this stu

751
752
753
754 **DATA AND MATERIALS AVAILABILITY**
753 Materials generated in this study will be
754 evaluate the conclusions of this work are
755 Materials This paper does not report or Materials generated in this study will be made available upon request. All data needed to

row evaluate the conclusions of this work are present in the paper and/or the Supplementary

Materials. This paper does not report evaluate the conclusions of this work are present in the paper and/or the Supplementary
755 Materials. This paper does not report original code. Any additional information required to
756 reanalyse the data reported in thi Materials. This paper does not report original code. Any additional information required to
756 Franalyse the data reported in this paper is available from the lead contact upon request.
757 **SUPPI EMENTARY MATERIALS** reanalyse the data reported in this paper is available from the lead contact upon request.
757
SUPPLEMENTARY MATERIALS
759 We provide supplementary files with supporting material -including Supplementary Tab

757
758
759
760 **SUPPLEMENTARY MATERIALS**

759 We provide supplementary files w

760 and Supplementary Figures 1 to 5 759 We provide supplementary files with supporting material, including Supplementary Table 1
760 and Supplementary Figures 1 to 5 (Figures S1-S5).
33 and Supplementary Figures 1 to 5 (Figures S1-S5).

761
762
763
764 762

It is made available under a CC-BY-ND 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.10.30.23297774;](https://doi.org/10.1101/2023.10.30.23297774) this version posted October 31, 2023. The copyright holder for this preprint

-
-
- 1018 variants/ (accessed 6.20.23).

1019 Wickham, H., 2016. ggplot2: Elegant Graphics for Data Analysis., Use R! Springer International

1020 Publishing. https://doi.org/10.1007/978-3-319-24277-4

1021 Wickham, H., Françoi 1019 Wickham, H., 2016. ggplot2: Elegant (1020 Publishing. https://doi.org/10
1021 Wickham, H., François, R., Henry, L., I
1022 Grammar of Data Manipulati(1023 Wickham, H., Hester, J., Francois, R., I
- Publishing. https://doi.org/10.1007/978-3-319-24277-4
1021 Wickham, H., François, R., Henry, L., Müller, K., Vaughan, D., Software, P., PBC, 2023a. dplyr: A
1022 Grammar of Data Manipulation.
1023 Wickham, H., Hester, J., 1021 Wickham, H., François, R., Henry, L., Müller, K., Vaughan, D., Soft
1022 Grammar of Data Manipulation.
1023 Wickham, H., Hester, J., Francois, R., Bryan, J., Bearrows, S., Posit
1024 com/mandreyel/ (mio, implementatio Grammar of Data Manipulation.

1023 Wickham, H., Hester, J., Francois, R., Bryan, J., Bearrows, S., Posit, PBC, library), https://github

1024 com/mandreyel/ (mio, implementation), J.J. (grisu3, implementation), M.J. (gris 1023 Wickham, H., Hester, J., Francois, R., Brya
1024 com/mandreyel/ (mio, implemer
1025 readr: Read Rectangular Text Dat
1026 Wickham, H., Pedersen, T.L., Software, P.
1027 Wilke, C.O., 2020. cowplot: Streamlined I 1024 com/mandreyel/ (mio, implementation), J.J. (grisu3, implementation), M.J. (grisu3, 202
1025 readr: Read Rectangular Text Data.
1026 Wickham, H., Pedersen, T.L., Software, P., PBC, 2023c. gtable: Arrange "Grobs" in Tab
-
-
- 1025 readr: Read Rectangular Text Data.

1026 Wickham, H., Pedersen, T.L., Software, P., PBC, 2023c. gtable: Arrange "Grobs" in Tables.

1027 Wilke, C.O., 2020. cowplot: Streamlined Plot Theme and Plot Annotations for "ggp 1026 Wickham, H., Pedersen, T.L., Software, P., P
1027 Wilke, C.O., 2020. cowplot: Streamlined Plo
1028 Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., I
1029 X., Mishra, N., Lu, J., Shan, H., Jiang,
1030 viral RNA in faeca 1027 Wilke, C.O., 2020. cowplot: Streamlined Plot Theme and Plot Annotations for "ggplot2."

1028 Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., Dong, X., Yin, H., Xiao, Q., Tang, Y., Qu, X., Kua

1029 X., Mishra, N., Lu, 1028 Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., Dong, X., Yin, H., Xiao, Q., Tang, Y., Qu, X., Kua
1029 X., Mishra, N., Lu, J., Shan, H., Jiang, G., Huang, X., 2020. Prolonged presence of S
1030 viral RNA in faecal sam Wu, Y., Guo, C., Tang, L., Hong, Z., Zhou, J., Dong, X., Yin, H., Xiao, Q., Tang, Y., Qu, X., Kuang, L., Fang
1029 X., Mishra, N., Lu, J., Shan, H., Jiang, G., Huang, X., 2020. Prolonged presence of SARS-CoV-2
1030 viral R 1030 X., Mishra, N., Lu, J., Mishra, M., Shang, G., Mishra, J., J., 2020. Prolong. Process.
1031 https://doi.org/10.1016/S2468-1253(20)30083-2
1032
- 1031 bittps://doi.org/10.1016/S2468-1253(20)30083-2
1032 bittps://doi.org/10.1016/S2468-1253(20)30083-2 1032 **https://action.**

1032